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Abstract 
 
Mature T-cell malignancies comprise a heterogeneous group of diseases with widely 
variable clinical courses, ranging from indolent, slowly progressing to rapidly 
progressing disease, leading to death. While some compounds have been found to be 
active in these diseases, much work remains to be done to characterize the disease 
entities genetically and molecularly and develop effective therapeutic options. Recent 
studies have found recurrent genetic mutations in the JAK/STAT pathway that 
contribute to the pathogenesis of T-LGL leukemia and PLL leukemia. The aim of this 
PhD project was to reveal new somatic mutations underlying different mature T-cell 
malignancies and further elucidate their functional impact on the pathogenesis of the 
disease. Furthermore, ex vivo drug screening of selected patient samples was applied 
in an effort to find clinically relevant drugs for the individual patient. 
 In the first study, exome sequencing was applied to three STAT-mutation 
negative T-LGL leukemia patients to elucidate the molecular background of this 
subset of patients. Mutations in genes associated with either the STAT-pathway 
directly (such as PTPRT) or T-cell activation were observed in all patients. These 
novel mutations are potentially biologically relevant and are associated with a similar 
disease phenotype as that of patients with mutations in the STAT3 gene. 
 In the second study, the exome sequencing of additional LGL leukemia 
patients revealed recurrent STAT3 mutations outside the hotspot SH2-domain. Further 
targeted amplicon sequencing of the entire STAT3 gene in a larger T-LGL cohort 
revealed mutations in the coiled-coil and DNA-binding domain present in 4% of 
patients. Similarly, in the third study, STAT5B mutations previously found to be rare 
in CD8+ LGL leukemia (2%) were discovered to be significantly over-represented in 
CD4+ cases (55%). For both studies, the activation and phosphorylation patterns of 
the new mutations were confirmed with functional assays.  
 In the fourth study, T-PLL leukemia patient samples were screened with a 
drug sensitivity and resistance testing platform to elucidate drug sensitivity patterns. 
The patients were divided by selective sensitivities to HDAC, PI3K/AKT/mTOR, 
HSP90, and JAK inhibitors. Intriguingly, all T-PLL samples were sensitive to the 
CDK inhibitor SNS-032, which was shown to inhibit distal TCR signaling and points 
to a centrally disturbed cell cycle regulation. Furthermore, different classes of p53 
activators showed T-PLL specific responses, indicating a previously unexplored 
targeted treatment for these patients. In combination with the drug responses, a 
targeted sequencing of known JAK/STAT mutations was applied together with gene 
expression profiling to molecularly characterize this rare disease. Strikingly, drug 
responses did not link to the presence of JAK/STAT mutations, TCL1A-activating 
translocations, or ATM deletion status, suggesting that screening for recurrent genetic 
biomarkers does not readily translate into applicable deductions on effective 
therapeutic strategies in T-PLL. However, the ex vivo drug response data enabled the 
discovery of new drug classes with potential efficacy in T-PLL. 
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Introduction 
 
Mature T-cell leukemias are a group of uncommon lymphoid neoplasms. These 
disorders have very variable clinical features, ranging from indolent to rapidly 
progressive diseases, ultimately leading to death. Cytogenetic aberrations and, more 
recently, recurrent genetic mutations have been found to contribute to their 
pathogenesis1. Conventional chemotherapy lacks significant effect in this group of 
diseases, and therapies vary from immunosuppression to treatment with antiviral 
agents and monoclonal antibodies.  
 In T-cell large granular lymphocytic leukemia (T-LGLL), the disease-driving 
cells are differentiated effector memory T-cells that are resistant to apoptosis by 
activation-induced cell-death (AICD). Many anti-apoptotic pathways are known to be 
activated in T-LGLL, one of the most studied being the Janus kinase (JAK)/signal 
transducer and activator of transcription (STAT) pathway controlling the transcription 
of proteins connected to cell cycle control and proliferation. The recent discovery of 
activating somatic mutations in the SH2-domain of STAT3 in 40% of T-LGLL 
patients has further highlighted the JAK/STAT pathway as a driver of T-LGLL 
pathogenesis2. As the diagnosis of T-LGLL is often based upon the examination of 
clonal expansions in the T-cell population, which are also frequently seen in non-
malignant conditions following antigen exposure, STAT3 mutations provide a novel 
diagnostic biomarker for this disease. Even so, over half of T-LGLL cases are STAT-
mutation negative, raising the question of what is driving their disease genetically. 
 T-cell prolymphocytic leukemia (T-PLL) is, in contrast to the indolent T-
LGLL, an aggressive disease of mature T-cells with an urgent need for targeted 
therapies in light of its notorious chemo-refractory behavior. Currently, the best 
treatment for T-PLL is the monoclonal antibody alemtuzumab, which has prolonged 
the median overall survival up to 20 months, but responses are still transient and 
relapses inevitable3. Cytogenetic abnormalities are seen in all cases of T-PLL, the 
most commonly seen being translocations in TCL1A and deletions in ATM. The 
activation of the JAK/STAT pathway has also been established with activating 
mutations in 76% of T-PLL patients4. Given these recent findings, the inhibition of 
JAK/STAT pathway activation remains a promising treatment opportunity. 
Translating the recent genomic discoveries in mature T-cell leukemias into 
clinically actionable therapy poses a significant challenge. Hopefully a better 
understanding of the pathogenesis of these disorders will lead to more precise therapy 
for patients afflicted with this difficult-to-treat group of diseases.  
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Review of the literature 
1. The tale of T-cells 
1.1. Lifespan of a T-cell 
Peripheral T lymphocytes as a population comprise of a mixture of naïve, effector, 
and memory cells. T-cells develop from lymphoid progenitors in the bone marrow 
that also give rise to B lymphocytes. A few of these progenitors migrate through 
circulation to the thymus, where the T lymphocytes mature5.	  The recirculating pool of 
mature T-cells is formed during childhood through the continuous release of naïve T-
cells from the thymus into the blood. In adults, the pool of mature T-cells is relatively 
self-sufficient, and the input of new T-cells from the thymus declines. Studies on T-
cell turnover indicate that most peripheral T-cells can remain in a resting state for 
years in humans. An analysis of the phenotype of dividing vs. non-dividing cells 
indicates that naïve T-cells are long-lived resting cells, while most effector and 
memory T-cells have a faster turnover6. The estimated lifespan of circulating T-cells 
is 6 months to 1 year, while effector cells have lifespans of only a few weeks.  
1.2. The T-cell receptor 
The developing thymocytes pass through a series of distinct phases marked by 
changes in the expression of the T-cell receptor (TCR) but also different cell-
surface proteins such as CD3, CD4, and CD8. These antigens can be used as 
markers for T-cells at different stages of development7. The earliest cell 
population in the thymus does not express any of these proteins, and therefore 
they are called “double negative” thymocytes (CD4-CD8-)8. These cells include 
precursors that give rise to two T-cell lineages with different TCRs; the majority 
population of αβ and the minority population of γδ. αβ T-cells later divide into 
either CD4+ helper cells or CD8+ cytotoxic cells7. 
Each T-cell harbors on its surface about 100,000 antigen receptors that all 
recognize the same epitope. The TCR must undergo extensive rearrangement to 
give rise to cells that recognize all different antigens (called the TCR repertoire). 
The TCR is made up of two different protein chains that are produced by a 
combination of the deletion and joining of variable (V), diversity (D), and joining 
(J) gene segments to produce a unique antigen receptor9. In developing 
thymocytes, the γ, δ, and β genes rearrange almost simultaneously. If a functional 
γδ receptor is formed before a functionally rearranged β-chain, the precursor 
commits to the γδ lineage by halting further gene arrangement10. The production 
of a functional β chain and signaling by the pre T-cell receptor commits the 
precursor to the αβ lineage, where both CD4 and CD8 co-receptor proteins are 
expressed on the cell surface (double positive thymocytes)8. αβ TCRs are more 
common and present in 90–95% of T-cells, while γδ TCRs usually present only in 
around 5% of mature T-cells. Mature αβ T-cells have an extensive variety of 
TCRs, which means that they can recognize almost any antigen and therefore 
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have an important role in the adaptive immune system. γδ T-cells have a more 
limited TCR variety, but, in contrast, they possess the ability to respond to intact 
antigens. This quality places them in between the innate and adaptive immune 
system11. 
1.3. Subtypes of T-cells 
The further development of the T-cell is entirely determined by the interaction 
between the TCR and the self-peptides presented by the major histocompatibility 
complexes (MHC) on the thymic stroma. T-cells that react too strongly to the 
presented peptides are automatically deleted in the thymus by antigen-presenting 
cells (APCs) in a process of negative selection. On the other hand, CD4+ CD8+ 
thymocytes, whose receptors interact normally with the peptide:MHC complexes, 
undergo positive selection and later become mature CD4+ or CD8+ T-cells. By 
the end of thymic selection, mature thymocytes ready for export to the periphery 
will stop expressing one of the co-receptors. Simply put, the co-receptor 
expression depends on the class of MHC molecule the thymocyte interacted with 
during the selection; contact with MHC class I molecules is required for cytotoxic 
CD8 T lymphocyte development, while class II molecules produce CD4 helper T-
cells12. 
Mature CD8 cytotoxic T-cells kill cells that display peptide fragments of 
intracellular pathogens (i.e., viruses) bound to MHC class I molecules at the cell 
surface (Fig 1). The naïve CD8 T-cells still need to be activated or primed by 
APCs before becoming cytotoxic. Mature dendritic cells often activate CD8 T-
cells, because they naturally exhibit the high intrinsic co-stimulatory activity that 
is needed to activate cytotoxic cells. They send signals through the TCR that 
induces IL-2 synthesis and drives the differentiation and proliferation process. 
The IL-2 stimulates cytokine receptors that in turn induce the production of 
granule components needed for lymphocyte-mediated toxicity13. As opposed to 
the NK-cells, cytotoxic T-cells can also undergo extensive expansion after 
activation, giving them a major role in response to prolonged antigen stimuli or 
high antigen loads.  
 After contact with peptide/MHC class II complexes on APC, CD4+ helper T-
cells initiate specific immune responses by secreting soluble proteins such as IL-2 or 
IFN-γ. These cytokines provide the required assistance for the activation and 
differentiation of other lymphoid cells. CD4+ T-cells also regulate immune responses 
through direct cell–cell contact and not only through secreted factors.  
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Figure 1. Mature CD8 cytotoxic T-cells kill cells that display peptide fragments of intracellular 
pathogens (i.e., viruses) bound to MHC class I molecules at the cell surface. Image edited from 
Ingenuity Pathway Analysis software. 
 
1.4. T-cell elimination 
When a T-cell encounters its antigen, it results in rapid proliferation of clonal effector 
cells over a few days. If the response continues uncontrolled it could cause harm, and 
therefore activated T-cells undergo activation-induced cell death (AICD)14. During the 
activation of cytotoxic T-cells, the transcription of both FAS and FAS ligands (FASL) 
is upregulated. If T-cells expressing FAS, a member of the tumor necrosis factor 
receptor family, meet other cells expressing FASL on their surface, Fas+ T-cells will 
undergo apoptosis. Without such a mechanism of T-cell elimination, the immune 
compartment would soon be overpopulated. Unfortunately, some tumors also express 
FASL, which provides them with an escape mechanism from immune surveillance by 
activated tumor-specific T-cells.  
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2. Mature T-cell malignancies 
 
T-cell neoplasms occur at various stages of T-cell maturation, with, for example, T-
cell acute lymphoblastic leukemia (T-ALL) developing at the early T-cell progenitor 
stage and peripheral T-cell lymphomas harboring neoplastic cells with markers of 
their more mature post-thymic counterparts (Table 1).  
Table 1. WHO classification of mature T and NK cell neoplasms 201615 
 
*Changes from the 2008 classification; provisional entities are listed in italics.  
 
Mature T-cell leukemias are a heterogeneous group of neoplasms with the common 
clinical feature of a mature neoplastic T-cell population in the blood circulation. The 
involvement of the bone marrow, lymph nodes, and spleen are also frequently present 
in these diseases. T-cell leukemias have widely different clinical behaviors. In T-cell 
large granular lymphocytic leukemia (T-LGLL), the clinical course is usually 
indolent, with the primary clinical manifestation being an associated cytopenia. On 
the other hand, T-cell prolymphocytic leukemia (T-PLL) is an extremely malignant 
process, with poor overall survival. Recent studies have added to our knowledge of 
the genetic background of these leukemias (Table 2) and have created a roadmap for 
potential future targeted therapies.	  	  
 
Table 2. Summary of recurrent genetic alterations in mature T-cell leukemias. Data 
compiled from references 2,4,16-23 
 
Mature'T)cell'and'NK)cell'neoplasms
T"cell&prolymphocytic&leukemia
T"cell&large&granular&lymphocytic&leukemia
Chronic(lymphoproliferative(disorder(of(NK(cells
Aggressive&NK&cell&leukemia
Systemic&EBV+&T"cell&Lymphoma&of&childhood*
Hydroa&vacciniforme"like&lymphoproliferative&disorder*
Adult&T"cell&leukemia/lymphoma
Extranodal&NK/T"cell&lymphoma,&nasal&type
Enteropathy"associated&T"cell&lymphoma
Monomorphic&epitheliotropic&intestinal&T"cell&lymphoma*
Indolent(T8cell(lymphoproliferative(disorder(of(the(GI(tract(*
Hepatosplenic&T"cell&lymphoma
Subcutaneous&panniculitis"&like&T"cell&lymphoma
Mycosis&fungoides
Sézary&syndrome
Primary&cutaneous&CD30&positive&T"cell&lymphoproliferative&disorders
&&&&&&&&Lymphomatoid&papulosis
&&&&&&&&Primary&cutaneous&anaplastic&large&cell&lymphoma
Primary&cutaneous&gamma"delta&T"cell&lymphoma
Primary(cutaneous(CD8(positive(aggressive(epidermotropic(cytotoxic(T8cell(lymphoma
Primary(cutaneous(acral(CD8+(T8cell(lymphoma*
Primary(cutaneous(CD4(positive(small(/medium(T8cell(lymphoproliferative(disorder*
Peripheral&T"cell&lymphoma,&NOS
Angioimmunoblastic&T"cell&lymphoma
Follicular(T8cell(lymphoma*
Nodal(peripheral(T8cell(lymphoma(with(TFH(phenotype*
Anaplastic&large&cell&lymphoma,&ALK&positive
Anaplastic&large&cell&lymphoma,&ALK&negative&*
Breast(implant8associated(anaplastic(large(cell(lymphoma(*
Disease Genetic/molecular0alteration Frequency Effect
T"cell&prolymphocytic TRA/D"TCL1&fusion 75% Aberrant&expression&of&TCL1&and&activation&of&the&AKT&pathway
leukemia TRA/D"MTCP1&fusion 10% Aberrant&expression&of&MTCP1&and&activation&of&the&AKT&pathway
JAK1/JAK3/STAT5b&mutations 75% Constitutive&activation&of&the&JAK/STAT&pathway
ATM&deletions/mutations 70% Impaired&DNA&damage&response
T"cell&large&granular STAT3&mutations 30"40% Constitutive&activation&of&the&JAK/STAT&pathway
lymphocytic&leukemia STAT5b&mutations Rare Constitutive&activation&of&the&JAK/STAT&pathway
Adult&T"cell&lymphoma JAK3&mutations 10% Constitutive&activation&of&the&JAK/STAT&pathway
CCR4&mutations 25% PI3K/AKT&activation
Sezary&syndrome TCF3&deletion 70% Enhanced&cell&cycle&progression
TP53&deletion 75% Impaired&DNA&damage&response
ARID1A&mutations 40% Chromatin&remodelling
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2.1 T-LGL leukemia 
2.1.1. Clinical characteristics and diagnosis 
 
In contrast with the other mature T-cell leukemias, T-LGLL is characterized as an 
indolent clonal proliferation of cytotoxic T-cells. The progression of T-LGLL is 
very slow, with a median survival after diagnosis >10 years. Although the disease 
can stay asymptomatic for a long time after diagnosis, about 60% of the patients 
become symptomatic during the course of the disease24. The most common 
complication associated with T-LGLL is neutropenia, and recurrent bacterial 
infections are therefore common initial clinical manifestations of LGL leukemia. 
Other complications associated with T-LGLL are anemia (50%), 
thrombocytopenia (20%), and splenomegaly, which is seen in two-thirds of 
patients. Autoimmune disorders are seen in 25–35% of T-LGLL cases, and 
especially common are Sjögrens syndrome and rheumatoid arthritis (RA) as well 
as pure red cell aplasia (in Asian populations)25.  
The diagnosis rests first and foremost on the observation of a persistent 
increase of LGLs in the peripheral blood. The phenotype of the cells are then 
analyzed to confirm the type of LGL leukemia, and the clonality is confirmed by 
performing TCRβ and γ gene rearrangement studies (PCR). Morphologically, the 
LGLs are large blood cells (15–18 µm) with a reniform or round nucleus 
surrounded by abundant cytoplasm containing azurophilic granules. Most patients 
present with an LGL count greater than 2.0×10^9/L, while the normal range is 
around 0.2–0.4×10^9/L26. A lower count may also be compatible with LGL, 
though establishing a diagnosis in such patients is more difficult.  
  LGL leukemia cells usually show a mature postthymic phenotype and 
typically co-express CD3+CD8+CD16+CD57+ antigens27. T-LGLs are also 
CD45RA+ and CD62L-, which is consistent with the effector memory T-cell 
phenotype. The T-cell receptor is typically of the αβ subtype although γδ-cases are 
clinically very similar to TCRαβ, with favorable survival of 85% at 3 years28.  
  Although some numerical and structural chromosomal abnormalities have 
been reported in individual cases of T-LGLL, there are no known recurrent 
abnormalities to make cytogenetic examination necessary. 
2.1.2. Pathogenesis of T-LGL leukemia 
 
T-LGLL is not a typical leukemia for two reasons. Firstly, the disease rarely 
progresses to a more malignant phenotype, and, secondly, no excessive 
accumulation of malignant cells usually exists. Actually, the clonal cells resemble 
normal antigen-activated CD8+ CD57+ effector cells. Both normal and malignant 
clones express perforin and Fas-L and have the ability to suppress neutrophil 
development in vitro29,30. While the etiology of the disease remains to be 
elucidated, there are a few theories about the origin of the clonal expansion seen in 
the cytotoxic T-cells.  
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As the disease-causing cells in T-LGLL are effector-memory cytotoxic 
lymphocytes (CTLs), this suggests that there could be some exogenous antigens 
causing the leukemic expansion. These could be of viral origin, as patients with 
NK-LGLL are often seropositive for p21e, an envelope protein found in human T-
cell lymphotrophic virus (HTLV-1). As the patients are negative to the virus itself, 
it has been hypothesized that a cellular or retroviral protein similar to this 
envelope epitope may play a significant role in LGL leukemia31. A few studies 
have analyzed the TCRβ complementarity determining region 3 (CDR3) repertoire 
in an effort to elucidate a possible antigen target. However, although the data 
suggest restricted use of the TCR repertoire in T-LGLL, no common antigens 
have been recognized32. 
Under normal physiological circumstances, activated CTLs are removed after 
antigen-driven expansion by apoptosis induced by different signaling pathways. One 
theory is that the cytotoxic T-cells in LGL leukemia fail to undergo apoptosis, which 
results in a persistent expansion of CTLs in the blood (Fig 2). This resistance results 
from the constitutive activation of a number of signaling pathways, such as the 
Fas/FasL33 and the JAK/STAT pathways34. For example, LGL leukemia cells have 
been shown to express high levels of Fas/FasL on their surface, yet they are resistant 
to the homeostatic apoptosis mediated by Fas33. The clonal transformation of LGLs 
may also be explained by a constitutive overexpression of pro-survival and anti-
apoptotic transcription factors. One example is STAT3, which is a transcription factor 
activated by phosphorylation leading to the activation of genes, affecting cell growth 
and apoptosis. STAT3 has been shown to be constitutively activated in T-LGLL, 
which may cause the inhibition of homeostatic apoptosis, such as the inhibition of the 
downstream Fas receptor signaling through the initiation of anti-apoptotic MCL-135. 
As additional proof, the blocking of the STAT3-signaling in T-LGLL is shown to lead 
to the reversal of the Fas resistance in leukemic cells35,36. 
 
 
Figure 2. Inciting events and clonal transformation in T-LGL leukemia. In normal 
circumstances, activated CTLs are removed by activation-induced cell death (AICD) to maintain 
homeostasis. In T-LGL an early transforming event may hit the expanded CTL clone, which leads to 
persistent clonal expansion. 
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The constitutive activation of STAT3 in T-LGLL patients is in part explained 
by the high frequency (40%) of activating mutations clustered in the Src-like 
homology 2 (SH2) domain of STAT32. In a smaller fraction of patients (2%), the 
JAK/STAT pathway is activated through STAT5B mutations19, causing a more 
aggressive disease course than is typical in T-LGL leukemia. However, the 
JAK/STAT pathway is also kept activated by non-mutational mechanisms. Increased 
IL-6 secretion by normal mononuclear cells has been described in T-LGLL patients, 
leading to increased JAK/STAT signaling. This activation is also supported by the 
frequent epigenetic inactivation of the suppressor of cytokine signaling 3 (SOCS3), an 
inhibitor of the JAK/STAT pathway37. In some patients, multiple different STAT3-
mutated clones are present at diagnosis38. These data suggest that T-LGLL is initially 
an oligoclonal process arising out of a background of dysregulated immune 
stimulation and STAT3 activation, with eventual dominance by a single clone. 
2.1.3. Treatment 	  
There is no standard treatment for patients with T-LGL leukemia. The 
management of asymptomatic patients is based on careful observation, as up to 
half of the patients may not require therapy. When there is a need for treatment, 
the goal is to alleviate the symptoms of the cytopenias rather than to eliminate all 
the malignant clones. Indications for treating patients are the development of 
recurrent infections, severe neutropenia (< 0.5×10^9/L), symptomatic anemia or 
thrombocytopenia, and symptomatic slenomegaly25. Other indications include 
autoimmune conditions (e.g., RA) associated with T-LGL leukemia requiring 
therapy and the presence of systemic symptoms.  
  To date, immunosuppressive therapy remains the main treatment, including in 
particular single agents methotrexate (MTX)39, oral cyclophosphamide, and 
cyclosporine (CyA)40. In patients with autoimmune disease, a common therapeutic 
approach is MTX with or without steroids41, but this is associated with frequent 
relapse42. Recent retrospective data suggest that cyclophosphamide may generate a 
more durable response in T-LGL leukemia patients43. In a limited number of patients 
it was found that complete molecular response (based on STAT3 mutation detection) 
may be more common in cyclophosphamide-treated patients than in those treated with 
MTX38. Novel therapeutic approaches indicated by preclinical data include STAT3 
inhibition35 and different demethylating agents aimed at overcoming the loss of 
SOCS3 activity37. 
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2.2. PLL leukemia 
2.2.1. Clinical characteristics and diagnosis  
 
T-cell prolymphocytic leukemia (T-PLL) is a rather infrequent, mostly aggressive 
post-thymic T-cell neoplasm. Comprising ~2% of mature lymphoid tumors, it is yet 
the most frequent of their primary leukemic forms. T-PLL typically follows an 
aggressive clinical course, but a minority of patients (~15%) may be asymptomatic at 
diagnosis. This indolent phase can prevail for a variable length of time and may 
extend to several years44. However, progression is unavoidable and may be very rapid 
when it occurs. This is a disease of older adults with a median age of onset of 61 years 
and occurs more frequently in males than females45.  
Clinical features include rapidly progressive lymphocytosis (>100×109/L), 
splenomegaly (66% of cases), hepatomegaly and/or lymphadenopathy (50% of cases), 
and some patients present with skin manifestations (~20%). The neoplastic cells in T-
PLL are intermediate-sized lymphocytes, with variably prominent nucleoli. 
Cytoplasmic blebbing is a characteristic morphologic feature. Phenotypically T-PLL 
tumor cells are CD2+CD3+CD5+CD7++CD52++ and CD4/8 variable.	  Most cases are 
CD4-positive; however, a significant subset exhibits the co-expression of both CD4 
and CD8, a feature that is uncommon in other mature T-cell malignancies46.  	   Due to the rareness of T-PLL, clinicians will often only see a case of T-PLL 
once every 5–10 years, which makes the recognition of the disorder challenging. 
Confirmation of the diagnosis requires a systematic approach and careful integration 
of morphology test results with immunophenotyping and cytogenetics. 
2.2.2. Recurrent genetic abnormalities 	  
Cytogenetic and/or molecular genetic abnormalities are seen in all cases of T-PLL47. 
Almost 75% of T-PLL cases harbor chromosome 14 inversions or translocations, 
resulting in aberrant activation of the proto-oncogene T-cell leukemia 1A (TCL1A)48. 
TCL1A is located in the 14q32 region and has been shown to promote malignant 
transformation of T lymphocytes in transgenic mice carrying the Tcl1 gene49. 
However, as most cases show complex karyotypes (>3 aberrations), TCL1A does not 
seem sufficient to drive the leukemogenesis of T-PLL alone. Furthermore, in the 
majority of T-PLL cases the ataxia telangiectasia mutated (ATM) gene, involved in 
the activation of the DNA damage checkpoint, is mutated or deleted. ATM is thought 
to be a tumor suppressor gene, as DNA double strand breaks result in rapid 
autophosphorylation and the activation of ATM, leading to checkpoint activation and 
the phosphorylation of substrates that regulate cell-cycle progression, DNA repair, 
and cell death. ATM is also known to interact with TCL1, which leads to the 
enhancement of nuclear factor kappa-B (NF-κB) and increased cell proliferation50.  
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Recently it was also reported that mutations in genes involved in the 
JAK/STAT pathway were found in 76% of T-PLL cases (Fig 3)4,51,52. A high 
frequency of mutations was found specifically in the pseudokinase domain of JAK3, 
which regulates the signaling activity of the protein. This leads to recurrent activation 
of JAK3, which causes constitutive STAT5 hyperphosphorylation and the 
deregulation of the JAK/STAT pathway. 
 
Figure 3. Mutations of the JAK/STAT pathway in T-PLL. Activating mutations of the JAK3 (30–42% of 
cases), STAT5B (36%), JAK1 (9%), and IL2RG (2%) genes were identified by Bellanger et al., 
Bergmann et al., and Kiel et al. in 2014. 
 
2.2.3. Treatment  
 
The prognosis for T-PLL patients is poor due to non-responsiveness to conventional 
chemotherapy, resulting in a median survival of only 4 months for non-responders45. 
Currently, the best treatment for T-PLL is alemtuzumab, a monoclonal antibody that 
targets CD52+ mature lymphocytes for destruction but not the stem cells from which 
they are derived53. This treatment has prolonged the median survival to up to 20 
months, but the response is transient and should be followed by consolidation with a 
hematologic stem cell transplant (HSCT) when possible3. This regimen extends the 
median survival to >4 years, but relapse and toxicity post-HSCT remain problematic. 
Recently, sequential combination chemoimmunotherapy using fludarabine, 
mitoxantrone and cyclophosphamide followed by alemtuzumab consolidation (FCM-
A) was examined in both previously treated and untreated T-PLL patients54. FCM-A 
was associated with a favorable overall response rate of 92% in this study, with 
median progression-free survival (PFS) of approximately 1 year. Single-agent 
bendamustine has some efficacy in alemtuzumab-refractory T-PLL, with an overall 
response rate of 53% and a PFS of 5 months55. Given the suboptimal long-term 
response of T-PLL to current therapy and the increased understanding of its molecular 
pathogenesis, targeted therapies are being evaluated. Given the recent finding of 
frequent mutational JAK/STAT pathway activation, STAT inhibition seems to be a 
promising treatment opportunity. In one encouraging study, the treatment of primary 
T-PLL cells with pimozide, a selective STAT5 inhibitor, resulted in a significant 
reduction of cell proliferation and viability4. 
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3. JAK/STAT signaling in hematologic malignancies 
 
The JAK/STAT pathway has a central role in the signaling of cytokines by regulating 
cell growth, differentiation, survival, and immune response56. Due to its critical roles 
in hematopoietic development, it is not surprising that it plays an important oncogenic 
role in lymphoproliferative malignancies57.	  Many cancers and blood malignancies 
have been associated with the constitutive activation of the STAT family of proteins, 
which as a rule is dependent upon JAK-mediated tyrosine phosphorylation for 
transcriptional activation58.	  In particular, activated JAK1/STAT3 and JAK2/STAT5 
have been shown to facilitate T-cell transformation59.  
3.1 Overview of the JAK/STAT pathway 
The human genome codes for four JAK (JAK1, JAK2, JAK3, and tyrosine kinase 2 
[TYK2]) and seven STAT (STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, 
and STAT6) proteins, which mediate signaling through more than 30 cytokine 
receptors60. A recognizable feature of cytokine receptors is their pre-association with 
JAK proteins, which enhances traffic and stability61,62 and strict cytokine dependency 
for signaling. The receptors have high affinity for cytokines, and up to 50% of the 
biologic activity can be obtained at less than 10% receptor occupancy rates63. The 
binding of a cytokine to its receptor activates the pathway, which basally is 
completely inactive. Cytokine binding induces a conformational change that either 
changes the orientation of a preformed dimer64 or causes receptor 
dimerization/oligomerization65. As a consequence, JAKs, which are pre-bound to the 
receptors’ cytoplasmic region, become activated. This leads to cross-phosphorylation 
and receptor tyrosine phosphorylation, which creates binding sites for cytoplasmic 
proteins such as the STAT proteins66. Phosphorylation leads to STAT homo-
dimerization and translocation to the nucleus, where they act as transcription factors 
(Fig 4). In addition to STAT activation, JAK signaling also activates other pathways 
such as phosphatidylinositol-3’-kinase (PI3K), AKT/mammalian target of rapamycin 
(mTOR), and mitogen-activated protein kinase (MAPK). 
The JAK/STAT pathway regulates the formation of lymphocytes. Cytokines 
that bind to receptors containing the common γ chain, such as IL-2, IL-4, IL-7, IL-9, 
IL-15, and IL-21, are essential for the formation and function of T-, NK-, and B-
cells67. These receptors activate JAK1 through cytokine-binding chains and JAK3 
through the common γ chain68. Most receptor signaling via JAK1-JAK3 activate 
STAT3 and STAT569. STAT activation can be reversed by at least three different 
mechanisms: (1) protein tyrosine phosphatases (PTPs) dephosphorylating the tyrosine 
residues on STATs70, (2) SOCS suppressors binding to JAKs and cytokine receptors 
causing negative feedback71, and (3) the protein inhibitors of activated STATs (PIAS) 
blocking the DNA binding of STATs in the nucleus72. Substantial evidence has 
revealed that constitutively active cytokine receptors (obtained by in vitro 
mutagenesis73) lead to permanent signaling. Therefore, constitutively active STAT 
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proteins in the nucleus somehow overcome these mechanisms of negative regulation, 
eventually leading to oncogenesis74. 
 
 
 
Figure 4. Cytokine receptors exist on the cell surface in an inactive state bound to JAKs via their 
cytosolic domains. The binding of a specific ligand (e.g., interleukins) induces a conformational 
change in the preformed dimer, leading to tyrosine phosphorylation and the cross-activation of JAKs, 
which phosphorylate intracellular receptor tyrosine residues. In turn, the phosphorylated residues 
attract signaling adaptor proteins that recognize specific tyrosine phosphorylated sequences. Various 
adaptor proteins become substrates of JAKs, triggering signaling cascades. Cytokine receptors are 
linked to the STAT, Ras–MAPK, and PI3K–AKT pathways, which converge at the nucleus and regulate 
gene expression. Pathway edited from Ingenuity Pathway Analysis software. 
3.2. The importance of JAK/STAT signaling in hematopoiesis 
The importance of the JAK/STAT pathway in the hematopoietic system has been 
demonstrated with various murine knockout models. For instance, Jak1-deficient 
mice die shortly after birth with immunological abnormalities phenotypically 
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resembling severe combined immunodeficiency, while Jak2-deficient mice die in 
utero as a result of fetal anemia75,76. The loss of JAK3, which is predominately 
expressed in NK-, T- and B-cells, results in a loss of both T- and B-cells due to the 
absence of IL-7 receptor signaling both in mice and humans77. STAT-deficient mice 
also exhibit a variety of immunodeficiency phenotypes. Stat1-deficiency leads to a 
failure to efficiently respond to microbial and viral infections as a result of impaired 
interferon signaling78. IL-6 and IL-21 signaling is crucial for TH17 differentiation, 
which explains why mice lacking Stat3 present with defects in TH17 differentiation, 
and mice with high STAT3 activity show an accumulation of TH17 cells79,80. The 
STAT protein family is part of many transcription factors that are involved in the 
determination of T-cell fates81. STAT4 and STAT6 are respectively considered to be 
TH1- and TH2-signature transcription factors82,83. The functions of STAT5 in different 
cell types have been extensively studied, revealing that STAT5 is a key regulator of 
myelopoiesis and lymphocyte development, proliferation, and differentiation. STAT5-
deficient mice suffer from a severe combined immunodeficiency-like phenotype84. On 
the other hand, overexpression or hyper-activation of STAT5 results in an expansion 
of CD8+ T-cells in mice85. 
3.3. STAT3 and STAT5 activation in cancer 
Tyrosine kinases (JAKs and TYK2) are often activated by genetic or epigenetic 
alterations in cancer, causing STAT activation as a secondary event. The effects of 
this constitutive activation depends upon the cell type and co-activating proteins. 
STAT3 can promote tumor growth through downregulation of the transcription of 
tumor suppressor TP53, upregulation of the transcription of antiapoptotic proteins 
(BCL-XL and MCL-1), and prevention of cell cycle arrest86. Aberrant STAT3 
activation has been observed in head and neck cancer, multiple myeloma, and several 
hematological malignancies such as AML, where it is associated with a shorter time 
of disease-free survival87,88. In autoimmune disorders, IL6-STAT3 activation has been 
observed in RA, psoriasis, and multiple sclerosis89. In hyper-IgE syndrome patients, 
germline mutations are seen in the DNA-binding and SH2-domain of STAT390,91, 
where the protein has a dominant negative effect; co-expression of wt and mutated 
STAT3 leads to the impaired DNA-binding and transcriptional ability of STAT3. 
Also, patients with severe autoimmune diseases, including type 1 diabetes92 and 
immunodysregulation polyendocrinopathy enteropathy X-linked–like syndrome 
(IPEX)93, have been found to harbor activating heterozygous germline mutations in 
the DNA-binding domain 93,94. In addition to the high frequency of STAT3 mutations 
in T-LGLL, somatic alterations of STAT3 have also been found in other diseases—
including acute T-cell lymphoma, hepatosplenic T-cell lymphoma, γδ-T-cell-derived 
lymphomas, NK leukemia, myelodysplastic syndrome, NK/T-cell lymphomas, 
peripheral T-cell lymphoma not otherwise specified, diffuse large B-cell lymphoma, 
and angioimmunoblastic T-cell lymphoma—making up for more than 250 identified 
cases in total95-100. Interestingly, all these mutations are found within the SH2-domain 
of STAT357. 
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Constitutive STAT5 activation is seen in many myeloproliferative diseases 
(MPDs), such as chronic myeloid leukemia (CML), where the oncogenic BCR-ABL1 
tyrosine kinase activates STAT5 and blocks apoptosis through the transcription of 
BCL-XL101. In other MPDs, such as polycythemia vera, myelofibrosis and essential 
thrombocytemia, STAT5 activation is commonly caused by an activating V617F 
mutation in the JH2 domain of JAK2102. Other somatic JAK-mutations have been seen 
in both adult and pediatric ALL-patients, and, more recently, activating STAT5B 
mutations were also found in T-ALL cases103. In comparison to the large number of 
patients who were identified with STAT3 mutations, the somatic N642H mutation in 
STAT5B was reported in less than 100 cases in different hematopoietic malignancy, 
inducing γδ hepatosplenic T-cell lymphomas, LGLL, enteropathy-associated T-cell 
lymphoma, and T-PLL4,19,95,104. 
3.4. Targeting the JAK/STAT pathway  
As described above, STAT proteins are constitutively activated in a majority of 
hematological malignancies. Although the impact of the JAK/STAT pathway on 
cancer development and progression has become apparent, targeting this pathway is 
challenging due to its pleiotropic nature. Considerable effort has been put forth to 
develop JAK/STAT inhibitors, and currently many JAK kinase inhibitors are being 
tested in clinical trials for leukemia105. Two of the most promising JAK inhibitors are 
ruxolitinib and tofacitinib. Ruxolitinib potently targets JAK1 and JAK2, while 
tofacitinib inhibits JAK1, JAK2, and JAK3 with nanomolar potency106. In early 2016, 
ruxolitinib was used in 27 active clinical trials for leukemia (mostly phase II), 
targeting MPDs, ALL, and Hodgkin’s lymphoma. Tofacitinib entered clinical trials as 
a treatment for RA, and many phase II trials have been completed107.  	   In addition to JAK-targeting drugs, the targeting of members of the STAT 
protein family is very promising in the search for effective cancer therapies. Recently, 
it was shown that a molecule already developed, pimozide, was capable of inhibiting 
STAT5 activation in BCR-ABL cell lines108. There are many strategies for targeting 
STAT proteins, including using peptides to bind and inhibit STAT production and 
activation or using small molecules to bind directly to the SH2 domain109. Since 
STAT3 and STAT5 are the most active family members of all seven STAT proteins 
in many cancers, many attempts are being made to produce specific STAT3 or 
STAT5 inhibitors. From the many inhibitors developed, only a few have entered 
phase I clinical trials, such as AZD9150 and OPB-31121110,111. In addition, a number 
of inhibitors targeting the SH2 domain of STAT5 are presently in development with 
promising potential112. 
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4. Functional genomics for personalized therapy 
 
The molecular characterization of leukemic malignancies is changing not only the 
understanding of these diseases but also the way the patients are diagnosed and 
treated. Already a few of the current diagnostic subsets set by the World Health 
Organization (WHO) have been defined by genetic parameters instead of the more 
traditional criteria such as the morphology and histology of the cells and tissues. The 
development towards the genetic profiling of cancer subtypes has been spurred on by 
the technological revolution of deep sequencing, and, although this knowledge is by 
itself exciting from a biological point of view, genetically driven medicine requires 
the translation of this information to personalized therapeutic solutions for patients. 
This requires not only the subdivision of diseases into subgroups with operationally 
important mutant genes but also knowledge of pathways that are dysregulated as a 
consequence and the ability to match the right cocktail of drugs with the pathways 
driving the pathogenesis. This leap will require the integration of genomic 
information with functional information about the drug sensitivity patterns of cancer 
cells (Fig 5).  
Figure 5. Functional genomics approach: current and future. To define the functional genomic 
landscape of leukemia, genomic and drug sensitivity analyses of primary leukemia are being performed 
in parallel. Sequencing reveals a large number of mostly rare genetic events, while functional 
screening shows patterns of drug sensitivity with an unclear genetic background. By integrating these 
data streams, it is possible to identify pathogenetically important and clinically actionable genetic 
events. This builds towards a future in which personalized, targeted therapies are prescribed solely on 
the basis of the rapid genomic analysis of individual patient tumor specimens.113 
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4.1. Next-generation sequencing 
For over two decades the gold standard of sequencing was Sanger sequencing, with 
which the major milestone of sequencing the first human genome was 
accomplished114. The major benefit of second generation or next generation 
sequencing (NGS) is the ability to produce a large amount of sequencing data faster 
and cheaper than was ever possible with Sanger sequencing. Commonly used 
applications of NGS are whole genome sequencing, whole exome sequencing (WES), 
RNA sequencing, and targeted amplicon sequencing. All these NGS methods have 
several steps in common that can be grouped as template preparation, sequencing and 
imaging, genome alignment and assembly, and data analysis115. 
4.1.1. Exome sequencing 
 
Over the last 10 years, exome sequencing has been applied to thousands of patients 
suffering from genetic diseases. Sarah B. Ng et al. were the first to report about the 
success of the technique in Nature (2009)116. They managed to rediscover a 
previously known mutation that causes Freeman-Sheldon syndrome by sequencing 
the exomes of a four-member family. Since then the technique has been responsible 
for a string of successful new discoveries, including mutations in different forms of 
cancer and leukemia. Both Yan et al. (Nature Genetics 2011)117 and Grossmann et al. 
(Blood 2011)118 reported the discovery of recurrent somatic mutations in different 
subtypes of acute myeloid leukemia (AML) by exome sequencing.  
With exome sequencing, the amount of sequence that is covered is 
reduced from 3,000 Mb to about 30 Mb scattered across 180,000 exons in the 
genome116. The sequencing of the protein-coding regions of the genome is not 
only timesaving compared to whole-genome sequencing but it is also more likely 
to detect relevant mutations. It has been estimated that up to 85% of disease-
causing mutations can be found in the exome regions alone119. Research suggests 
that the sequencing of exomes in small numbers of unrelated individuals with a 
shared monogenic disorder is as efficient as a genome-wide scan for the causative 
gene116.  
 To perform exome sequencing, it is crucial to efficiently isolate the exons that 
are spread out in the genome. There are a few different methods for capturing this 
genomic subset, and companies such as Agilent, Roche/Nimblegen, and Febit offer 
commercial kits implementing these methods. The most commonly used methods are 
solid-phase and liquid-phase hybridization. In solid-phase hybridization, probes 
complimentary to the sequences of interest are fixed to a solid support (i.e., 
microarray or filter) and allowed to hybridize with total DNA120. The desired 
fragments are thereby attached via the probes to the solid support while the non-
targeted fragments are washed away. The enriched exome DNA can then be eluted 
and sequenced. The principle is the same for liquid-phase hybridization, but instead of 
the probes being attached to a solid matrix, they are biotinylated. The probes are 
allowed to hybridize with their target DNA and are then bound to magnetic 
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streptavidin beads121. The commercial kits that are currently available have chosen to 
target the human consensus coding sequence regions122, covering about 83% of the 
RefSeq coding exon bases, or 29 Mb of the genome. No exome capture method is 
fully efficient, which needs to be considered in the interpretation of the sequencing 
results. 
 In the past it was always problematic to sequence cancer genomes due to 
the fact that any given tumor sample would always be a mixture of cancerous and 
healthy cells. Using Sanger sequencing was inefficient, as it could not detect 
genomic alterations prevalent at a low frequency in clinical samples123. Exome 
sequencing, on the other hand, enables the deep coverage that is needed for 
studying cancer tissue. Any given sequence is read between 10–100 times, which 
means that the probability for the cancer cell genome to be sequenced is much 
higher than in Sanger sequencing. Exome sequencing can be used to detect 
mainly different point mutations, small insertions and deletions (indels), and copy 
number variations (CNVs).   
4.1.2 Targeted amplicon sequencing 
 
Targeted next-generation sequencing panels to identify genetic alterations in cancers 
are increasingly becoming an integral part of clinical practice. The deep sequencing of 
PCR amplicons (> 1000x coverage) allows for the efficient characterization of known 
gene targets and is especially useful for the discovery of rare somatic mutations in 
complex samples (such as tumors mixed with germline DNA). Illumina amplicon 
technology uses a pair of oligonucleotide probes designed to target and capture 
regions of interest, followed by NGS. The multiplexing of hundreds to thousands of 
amplicons reduces the sequencing costs and turnaround time compared to broader 
approaches. This highly multiplexed approach facilitates research by sequencing 
multiple genes simultaneously at approximately the same cost as a single-gene assay.
 Amplicon sequencing allows researchers to sequence 16–1,536 targets at a 
time, spanning 150–1,500 bp per target, depending on the library preparation method 
used. To enrich the desired amplicons, primers with adapter tails are used, and the 
DNA fragments are attached to a glass slide by the adapter sequences124. The adapter-
specific primers form template clusters through the process of bridging amplification. 
These clusters of identical templates are essential, as most imaging systems are unable 
to detect single fluorescent signals115. Next, a fluorescent nucleotide with a 
terminating group is added to the template, and lasers identify the nucleotide via 
fluorescence detection. Finally, the terminating group is cleaved to enable the start of 
the next nucleotide incorporation in a process called cyclic reversible termination. 
4.1.3. NGS coverage and error profiles  
 
For a variant to be detected with high reliability the site needs to be adequately 
covered by a sufficient amount of reads. The detection of variants in a low-coverage 
area is more difficult, and the minimum median coverage recommended for NGS 
experiments is 20–30-fold to ensure the proper detection of variants125. However, it is 
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important to note that minimum coverage is highly dependent on many aspects of the 
platform and assay, including base-call error rates, quality parameters, and analytical 
pipeline performance126. 
Every NGS platform has its own error profile caused by the introduction of 
erroneous mutations during the template amplification stage. These are 
indistinguishable from true variants of the source DNA and can also affect the correct 
alignment of the reads127. A better knowledge of the error patterns is essential for 
sequence analysis and vital for drawing valid conclusions. For amplicon sequencing 
with the Illumina MiSeq platform, the library preparation method and the choice of 
primers are the most significant sources of bias and cause distinct error patterns128. 
These errors can be filtered out by sequencing a reference DNA sample with a known 
sequence in parallel to give an estimate of the error profile of the actual sample 
sequenced and analyzed.  
4.1.4. Analyzing sequence data 
 
Sequencing results in a huge amount of data, which to be significant needs to be 
processed with bioinformatical tools. The nucleotide sequence of a template is 
called a read (usually between 25–250 bp long) and these are aligned to a known 
reference sequence (in this case the human genome) with different aligner tools 
(e.g., Burrows Wheeler aligner [BWA]129). Next, variants are called using tools 
such as Varscan130, which is an identification algorithm developed for the 
nomination of putative mutations, indels, and CNVs. When analyzing cancer 
exome data, a comparison of the tumor sample variants with the healthy germline 
data is essential to distinguish somatic mutations from germline variants. Putative 
somatic variants can be filtered with, for example, Varscan2131 and subsequently 
annotated for functional consequences at the gene/protein level and the 
evolutionary conservation of the mutation site132. A major dilemma in all 
sequencing studies is to distinguish driver mutations—which contribute to 
carcinogenesis—from passenger mutations that are an incidental consequence of 
the many cell divisions and genomic instability of cancer cells. Passenger 
mutations are thought to greatly outnumber driver mutations.	  Different databases 
can be used to filter out common variants seen in the population (SISu, dbSNP, 
ExAC) and to annotate the variants further for clinical relevance (Clinvar, 
COSMIC, OMIM)133. Sequencing data can also be visualized with different 
programs such as the Integrative Genomics Viewer (IGV) for manual curation of 
putative mutations.  
4.2. Drug sensitivity and resistance testing of cancer cells 
While the molecular characterization of a disease can give us clues into which 
pathways are activated and driving the disease, functional data from drug sensitivity 
assays inform about which drugs are effective, but the etiology of the mechanisms 
behind the response remains unknown. Combining both genetic and functional 
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information could hopefully bring us closer to new forms of treatment and also 
illuminate the biological background of pathogenesis. Lately, evidence has been 
accumulating that kinases are frequently deregulated in human cancer and leukemia, 
with one study reporting that as much as 70% of leukemia samples show 
hypersensitivity to one or more kinase inhibitors134. Unbiased cancer drug sensitivity 
studies focusing on targeted agents could therefore be used to link drug responses to 
genetic and clinical features. Previously, this strategy has proven successful in BCR-
ABL-driven leukemia, where axitinib was found to be effective in patients harboring 
the resistance-causing T315I mutation in ABL1135,136. On the other hand, the 
diagnosis of particularly drug resistance in individual patients would improve cancer 
treatment by avoiding ineffective treatments.  
Various assays for fresh tumor cell culture assays have been developed, but 
the principal steps—the isolation of cells, incubation of cells with drugs, and 
assessment of cell survival—are the same137. All methods measure the molecular 
processes of cancer cells, revealing cell activity and indicating cell growth or death. 
Frequently used methods are thymidine incorporation into cell DNA138 and the loss of 
cell ATP139. The comparison of different read-out methodologies has revealed the 
ATP-based luminescent assay to be very sensitive but also susceptible to the 
underestimation of drug potency and efficacy, especially for compounds interfering 
with DNA synthesis140. A major issue with drug screening assays is reproducibility; 
the assay set-up has a significant impact on the quantification of the drug response. 
This has been seen in the comparison of two major cell line screening programs (the 
Cancer Cell Line Encyclopedia [CCLE] and the Cancer Genome Project [CPG]), 
where discrepancies were found in the drug sensitivity data that were not mirrored in 
the gene expression profiles141,142. The observed differences were likely due to the lack 
of standardized protocols for the handling of the cells and the different concentration 
ranges, readouts, and scoring of the drug responses143. Several other factors, such as 
cell culture conditions and compound handling and storage as well as assay 
conditions, should be taken into account when comparing outcomes from different 
platforms.  
The primary data output of drug screening studies are compound dose 
response curves and associated drug response metrics, such as the half-maximal 
inhibitory concentration (IC50) and area under the curve (AUC). The IC50 is the most 
commonly used to evaluate drug sensitivity, but it has limited ability to fully capture 
the drug response information. In an effort to quantify the drug sensitivity data and 
make them more comparable between different samples, a single measurement termed 
drug sensitivity score (DSS) has been developed144. It takes into account all four 
curve-fitting parameters used to calculate the AUC in relation to the total area 
between 10% threshold and 100% inhibition (Fig 6). Furthermore, to detect cancer 
selective drug responses, DSS values detected in patient samples can be compared 
with DSS values from healthy samples to obtain a selective DSS (sDSS).  
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Figure 6. Schematic illustration of the selective DSS calculation (sDSS, the grey area). Dose-response 
parameters estimated through a logistic function model include IC50 , slope of the curve at IC50, and 
the bottom and top asymptotes of the curve (Rmin and Rmax).The two dose-response curves clearly show 
differential activity patterns, yet their relative IC50 is equal, showing an example in which IC50 is not 
informative enough for detecting selective responses in patient samples. 
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Aims of the study 
 
The aim of this PhD project is to reveal the somatic mutations underlying different T-
cell malignancies, such as LGL leukemia and PLL leukemia, and further elucidate 
their functional impact on the pathogenesis of the disease. Furthermore, in an effort to 
discover new treatment options for these patients, the ex vivo drug screening of 
selected patient samples was applied in an effort to find clinically relevant drugs for 
the individual patient. 
 
The project consisted of four parts: 
 
1. The pathogenesis of T-LGLL in STAT3 mutation-negative patients 
2. Further characterization of STAT3 mutations outside of the SH2-domain in T-
LGLL 
3. The discovery and characterization of STAT5B mutation spectrum in CD4+ T-
LGL leukemia 
4. Functional genomics with the amplicon screening of known mutations paired 
with drug sensitivity testing in T-PLL leukemia patients to discover novel 
drug targets 
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Patients and methods  
6. Patients and ethical permissions 
 
T-LGLL and PLL patients were diagnosed based on the WHO 2008 guidelines 
(studies I-IV). The samples were collected from Helsinki University Central Hospital 
(Finland), Oulu University Hospital (Finland), Penn State Hershey Cancer Center 
(USA), Cleveland Clinic (USA), Shinshu University Hospital (Japan), Queen Mary 
Hospital (China), Hospital Universitario de la Princesa (Spain), University Hospital 
Heidelberg (Germany), University Hospital Olomouc (Czech Republic), University 
Hospital Aachen (Germany), Mayo Clinic (Minnesota US), University Hospital 
Cologne (#11-319, Germany), and Saint-Louis Hospital (France). All studies were 
conducted in accordance of the principles of the Helsinki declaration and was 
approved by the Helsinki University Central Hospital Ethics Committee. Written 
informed consents were obtained from all patients and healthy controls in all studies. 
In study I, the molecular background of STAT-mutation negative T-LGLL 
patients was analyzed by WES of CD8+ tumor LGLs and healthy CD4+ cells. The 
mutations found were subsequently screened in a larger cohort of 113 STAT-negative 
T-LGLL patients. DNA used for the validation analyses was extracted from whole 
blood or mononuclear cells (MNCs).  
 Study II included the three T-LGLL patients previously exome sequenced and 
four new CD8+ STAT-negative T-LGLL cases. The STAT3 mutations outside of the 
SH2-domain were analyzed through amplicon sequencing from a cohort of 99 T-
LGLL patients previously confirmed to be STAT3 hotspot mutation negative. DNA 
was extracted from whole blood or MNCs.  
 In study III, WES was performed on CD4+ tumor cells and CD8+ healthy 
cells from three CD4+ T-LGLL patients. The STAT5B SH2-domain and 
transactivation domain was screened from CD4+ (n=8), STAT3-mutated CD8+ (n=37) 
and STAT-mutation negative CD8+ (n=58) T-LGLL patients. Additionally the same 
regions were screened with Sanger sequencing in Japanese and Chinese LGL-
leukemia cohorts consisting of CD8+ and CLPD-NK cases (n=57).  
 Study IV analyzed the molecular mutations and drug responses of T-PLL 
patients to find novel therapeutic options for this aggressive disease. From a cohort of 
70 T-PLL patients, DNA was extracted from MNC samples and known mutations of 
the JAK/STAT pathway were screened with targeted amplicon sequencing. 39 patient 
samples were further screened with the DSRT system, either fresh (n=4) or viably 
frozen (n=35). MNC samples from four healthy subjects were also screened and used 
as controls. For in vitro experiments, the Jurkat cell line was used. 
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7. Mononuclear cell separation 
 
Peripheral blood (PB) samples were collected from leukemia patients and MNCs 
were separated by using Ficoll-PaqueTM PLUS (GE Healthcare). The cells were 
either used immediately for CD8+ and CD4+ selection or viably frozen in liquid 
nitrogen. If frozen, FBS containing 10% dimethyl sulfoxide (DMSO) was added 
to protect the cells and the samples were stored in -70˚C for 24-48 h before 
transferring them into liquid nitrogen.  
8. Selection/sorting of lymphocytes 
 
In all studies, the cells were further sorted into CD4+ and CD8+ populations with 
either AutoMACS magnetic bead sorting (Miltenyi Biotech) or sorting by flow 
cytometry using BD Biosciences Multitest CD45, CD3, CD8 and CD4 antibodies. A 
small amount of cells from the sorted fractions were used to check the purity of the 
sorting with flow cytometry (FACS Aria, Beckman-Coulter Immunotech). 
9. TCR-Vβ flow cytometric analysis of peripheral blood 
 
In studies I-IV, clonal expansions in PB samples were assessed with the IO Test® 
Beta Mark TCR Vβ Repertoire Kit (PN IM3497, Beckman Coulter Immunotech), 
which is a kit for the quantitative determination of the TCR Vβ repertoire of 
human T lymphocytes using flow cytometry. The kit consists of 8 vials 
containing mixtures of conjugated TCR Vβ antibodies corresponding to 24 
different specificities covering approximately 70 % of the normal human TCR Vβ 
repertoire. To further characterize the expansions, the samples were also stained 
with CD3, CD4 and CD8 antibodies (BD Biosciences). 
10. DNA and RNA extraction 
  
DNA from whole MNC, CD4+ or CD8+ cells was isolated according to the 
Nucleospin® Tissue Kit instructions (Macherey-Nagel). RNA was extracted with 
the miRNeasy kit including DNAse I digestion (Qiagen) according to the 
manufacturer’s instructions. DNA and RNA concentrations were measured using 
Qubit® 2.0 Fluorometer (Invitrogen) and the quality was assessed with the 
Agilent 2100 Bioanalyzer (Agilent Technologies). 
11. Sequencing methods 
11.1. Capillary sequencing 
Based on exome sequencing results, specific primers were designed for candidate 
mutations using the Primer Blast search (http://blast.ncbi.nlm.nih.gov/, National 
Center for Biotechnology Information, Bethesda, MD, USA). PCR was performed on 
CD8+ and CD4+ DNA. PCR products were separated by gel electrophoresis and 
extracted from the gel using the Nucleospin Gel and PCR Clean-up Kit (Macherey 
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Nagel) or ExoSAP-IT PCR Product Clean-up (Affymetrix). The purified PCR 
products were then sequenced with BigDye™ v.1.1 Cycle Sequencing kit and the 
ABI PRISM® 3730xl DNA Analyzer. Sequences were analyzed using 4Peaks (v. 
1.7.2.) and Blast search. 
11.2. Exome sequencing 
Paired matched samples from each patient were used for exome sequencing in all 
studies. In studies I-II CD8+ cells were used as tumor samples while CD4+ cells 
represented the normal controls. In studies III-IV CD4+ cells represented the tumor 
fraction while CD8+ cells were used as control. 
3µg of each DNA library was fragmented with a Covaris S2 instrument. 
Sample libraries were processed according to NEBNext DNA Sample Prep Master 
Mix Set 1 manual (New England BioLabs) with some exceptions; All primers and 
oligonucleotides were custom ordered from Sigma Aldrich. Agilent captures were 
processed according to the Agilent SureSelect Target Enrichment System for Illumina 
Paired End Sequencing Library SureSelect Human All Exon and Human All Exon 
Plus v2.0.1 protocol with the following exceptions: 1µl of the captured library was 
used in five parallel 50µl amplification reactions in postcapture PCR. 1µl of 100µM 
NimbleGen PE POST1 and PE POST2 primers were used in each reaction. 12 cycles 
were used. Sequencing of exome and RNA sequencing libraries was performed using 
the Illumina GAII instrument. Exome sequencing libraries were sequenced as 82 bp 
paired end reads.  
11.3. Targeted deep amplicon sequencing 
Locus-specific primers were designed for study II, III and IV to cover the desired 
gene areas using Primer3 with user-defined parameters (http://primer3.wi.mit.edu/). 
After designing the locus-specific primer sequences (Table 3), sequence tails 
corresponding to the Illumina adapter sequences, were added to the 5′ end of the 
forward and reverse locus-specific primers, respectively. All oligonucleotides were 
ordered from Sigma-Aldrich. Sample preparation was performed according to an in-
house targeted PCR amplification protocol. Each amplicon was amplified in 
multiplexed PCR-containing locus-specific PCR primers carrying Illumina-
compatible adapter sequences, Illumina TruSeq Universal Adapter primer, and 
Illumina TruSeq Adapter primer with a sample-specific 6-bp index sequence (used for 
genetic barcoding of each sample). The locus-specific primers are present in limiting 
quantities and are thus consumed in initial cycles of amplification forming 
intermediate amplification products. In subsequent amplification cycles, the adapter 
primers further amplify these intermediate products forming an Illumina-compatible 
paired-end sequencing template.       
 Following PCR amplification, samples were purified using a Performa V3 96-
Well Short Plate (EdgeBio) and QuickStep 2 SOPE Resin (EdgeBio) and then pooled 
together without exact quantification. Purified sample pools were analyzed on an 
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Agilent 2100 Bioanalyzer (Agilent Technologies) to quantify amplification 
performance and yield. Sequencing of PCR amplicons was performed using the 
Illumina MiSeq instrument with MiSeq Control Software (version 1.2; Illumina). 
Samples were sequenced as 151-bp paired-end reads and two 8-bp index reads. 
 The sensitivity and reliability of the STAT amplicon sequencing platform was 
validated in a previous publication38. 
Table 3. Primer sequences for amplicon sequencing
 
11.4. Real-time quantitative PCR 
In study II, total RNA from the transfected HEK293 cells was extracted with AllPrep 
DNA/RNA/miRNA Universal Kit (Qiagen) after which the RNA was converted to 
cDNA (1 µg) with Superscript III reverse transcriptase (Thermo Fischer Scientific) 
using random primers. Expression levels of six known STAT3 target genes (SOCS3, 
JAK2, MYC, JUNB, BCL3, CCL2) were measured using iQ SYBR Green Supermix 
(Bio Rad) and the CFX96 Touch™ Real-Time PCR Detection System (Bio Rad). 
Site Forward+primer Reverse+primer Study
STAT3%exon%2 TCCCCATCACCTGTACCCAT TGACACCTGTGTTGGGCAAT
STAT3%exon%3 ACACTAACACCCGACTCTGC TGTATGCGTCGGCTTCAGAG
STAT3%exon%4 TCCATTCCTCCCAGACCAGG GCTCTGAAGCCTTTGTTCCG
STAT3%exon%5 CCGAGGCTTGTAACTTGCAT TTCCCTTCCTCTTGTGATGG
STAT3%exon%6 GACCAGGCTCCTTTGAGGAC CTCTTGGGGATACTGCCTGC
STAT3%exon%7 CCGATCTAGGCAGATGTTGG TTCCCTCAGGTCAAGGAGTTT
STAT3%exon%8 CTGTGGGCCTGCAGTTAAGA GTTCCTGCTCTGGAGTTGACT
STAT3%exon%9 AAGAGAAGATGGGCTCACGC TCCCCTTCTCCATCTCACCT
STAT3%exon%10 TGGAAAGAATGACCCTGGCC CACGTGGTAGAGTGAGAGGC
STAT3%exon%11 AATGCACCCCAAGGCTTTTG CCTCCCACAGTGCTGAGATT
STAT3%exon%12514 CAAGGAAAACACCCCAGTTG AAATAACAGGTGGTCAAAGTAGGC
STAT3%exon%15 ATTGCCAGATGGGATGCCAA CCACACCTGGCCTAAGAGTG
STAT3%exon%16 GAGGAGAACTGCCAGCTCAG CCTTTCATTCTGAGCCCCGT
STAT3%exon%17 AGGGAGAAGGGGTGAAATGC TGCCCCCTCCTTTTAGTTGG
STAT3%exon%18 CCTTGCCAGCCATGTTTTCC AACCTCTTGACCCCAAGCTG
STAT3%exon%19 GTGCACACTCTGTCCAACCT GCTTGAAGGCCCTGAACTCT
STAT3%exon%20 GGAGTCAAGGCCATCTCCAC TGGATGCCCTGTTAGCAATA
STAT3%exon%21 CCCAAAAATTAAATGCCAGGA GGTTCCATGATCTTTCCTTCC
STAT3%exon%22 CTCACCCAGTGTCCCATTCC GGCAGATGGAGCTTTCCAGA
STAT3%exon%23 GACCAGCTCTCGGTGTGTAC TGGAGACCAGAGTTTGATGGC
STAT3%exon%24 GGCACTTGTCTAAGAACAACAACA AGTTGCAGAGGGTGGACAAC
STAT5B%exons%14515 CTGACCTCAACAAATAGTAAGTACCC TTCCAAGTGTTACTCTGGTGTTC
STAT5B%exon16 TGTTGGGGTTTTAAGATTTCC CAAATCAGAATGCGAACATTG
STAT5B%exon%17 %CCCAGGGCTGAGACAGTTT% AGATTGCACCACCGTACTCC
STAT5B%exon%18 %TGGATTCCTTTGACCCCAGC AGATACCCCTTGGTCCCCTC
STAT5B%exon%19 %CTGGTGGCCTGTGGGGCTTG% TCTGTCTGTGGCCCCTCTGCT
JAK3%exon%11 TCTCTGGACCCCAGACTGAG GTCTCAACAGCAGCAGCAAC
JAK3%exon%12 CAAAGTGCTGGGATGACAGG GGCCTCAGGCATATGCTATAAT
JAK3%exon%15 GGATCCACTTCCTTGCCCTG GGTGTTTGAGAAGGGGAGGG
JAK3%exon%16 CTGAGGGTGAGAGGAGCAGT CCTGGAGAGTAAGTTCCTGGAG
JAK3%exon%18 TGAAAGTCCCTCTGCTGGTC CCTGCCATAATGCACAGAGA
JAK3%exon%19 TCACGTTCCCAGCCTACCTA TCACAGCTGGGCAAGGTAAG
JAK1%exon%13 TCTCAACCCATTGTGTTCCA GTTCCCATTGAGGACCCATT
JAK1%exon%14 CCACCCACCCCTTTGAAAGA ATTGATGTTCAGGGCCTGGG
JAK1%exon%15 ACCAGGCACACCTTTGTTCA AGGGGATGAAGGAGAGGACC
JAK1%exon%20 CCACCAGCTAGCATGTCAGA CTGTGTGTTCCGTGGCCTA
IL2RG%exon%8 ATGGCAACTGGTATTGGGGG %GAGTATGAGACGCAGGTGGG
IV
II
III,%IV
III
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Results were normalized against four housekeeping genes (NONO, PGK-1, GAPDH, 
LDHA), which showed uniform expression across all samples. Primer pairs are listed in 
Table 4. All reactions were run in triplicate wells and gene expression was quantified 
using the delta-delta Cq method. 
Table 4. Primer sequences for qPCR assay
	  
11.5. RNA sequencing 
In study IV, 1-3 ug of CD4+ total-RNA was used for depletion of ribosomal RNA 
(Ribo-Zero, Epicentre). The ribodepleted and purified (Nucleospin cleanup XS, 
Machery-Nagel) RNA was reverse transcribed to ds cDNA (SuperScript™ Double-
Stranded cDNA Synthesis Kit, Life Technologies). Random hexamers (New England 
BioLabs) were used for priming the first strand synthesis reaction and SPRI beads 
(Agencourt AMPure XP, Beckman Coulter) for purification of cDNA.  
 Illumina compatible Nextera™ Technology (Illumina, Inc.) was used for 
preparation of RNAseq Libraries. In this technology DNA fragmentation and tagging 
is performed by in vitro cut-and-paste transposition. 60ng of doublestranded cDNA 
was used instead of DNA. After tagmentation reaction the fragmented cDNA was 
purified with SPRI beads.  
 In order to add the Illumina specific bridge PCR compatible sites and enrich 
the library, limited-cycle PCR (5 cycles) was done according to instructions of 
Nextera system with minor modifications. For barcoded libraries, 50X Nextera 
Adaptor 2 was replaced with a bar coded Illumina®-compatible Adaptors from the 
Nextera Bar Codes kit (Illumina, Inc.) in PCR setup. SPRI beads were used for 
purification of the PCR-products and the library quality control was evaluated by 
Agilent Bioanalyzer (Agilent Technologies). Illumina HiSeq2000 platform was used 
for sequencing to produce more than 40x106 paired end reads with 100bp read length. 	  
 
 
 
Target'gene Forward Reverse
GAPDH AGCACCCCTGGCCAAGGTCA CCGGAGGGGCCATCCACAGT
SOCS3 CTTCGATTCGGGACCAGCCCCC GGCGGCGGGAAACTTGCTGT
STAT3 AGCGAGGACTGAGCATCGAGCA GCCCTTGCCAGCCATGTTTTCTTTG
MYC CAGCTGCTTAGACGCTGGATT GTAGAAATACGGCTGCACCGA
JAK2 GCTCAGTGGCGGCATGAT CACTGCCATCCCAAGACATTC
JUNB TGGTGGCCTCTCTCTACACGA GGGTCGGCCAGGTTGAC
CCL2 GTCTCTGCCGCCCTTCTGT TTGCATCTGGCTGAGCGAG
BCL3 CCACAGACGGTAATGTGGTG TATTGCTGTGGTGCAGGGTA
PGK1 CCCAGCTGTATTTCCAAAATGTCGC ACAGCAGCCTTAATCCTCTGGTTGT
LDHA CTCTGAAGACTCTGCACCCA GCCCAGGATGTGTAGCCTTT
NONO GCTCTGGACAGATGCAGTGAA CTGCTCTCGTTCCTTGTGAA
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12. Sequencing data analysis 
12.1. Variant filtering and visualization of exome data 
Raw Illumina sequence reads were trimmed of B blocks in the quality scores from the 
end of the read. After this, if any pair had a read shorter than 36 base pairs, the 
pair was removed. The quality scores were converted to Sanger phred scores using 
Emboss (version 6.3.1) and aligned using BWA (version 0.5.8c) against the human 
genome build hg19 primary assembly. After alignment, potential PCR duplicates 
were removed with Picard Mark Duplicates (version 1.32). A pileup file was 
generated with SAMtools pileup, while reads with mapping quality scores below 0 
where excluded. Somatic mutations were called with the VarScan 2.2.3 somatic 
mutation caller using the CD8+ sample as the tumor and the CD4+ sample as the 
normal control. The minimum number of tumor reads required was set to 7. Putative 
somatic mutations were annotated for functional consequences at gene and protein 
sequence levels and with Genomic Evolutionary Rate Profiling (GERP) conservation 
scores using Annovar. Variants present in 1000 Genomes Project (May 2011 data 
release) or dbSNP132 data sets were excluded from further analysis. Annotations 
were integrated and filtering was performed using a MySQL database. Missense, 
nonsense, frameshift, inframe coding indels and splice site mutations with VarScan 
somatic p-value below 0.01 were analyzed further. Alignments at candidate mutant 
loci were checked visually in IGV for alignment artifacts. Mutants with alignment 
artifacts were excluded from further analysis. Description of cellular and biochemical 
function was added manually to the remaining mutations and a set of mutations in 
genes deemed to be biologically relevant to leukemia pathogenesis based on expert 
opinion were selected for validation.  
12.2. Amplicon data analysis 
The data was analyzed using an in-house bioinformatics pipeline developed 
specifically for reporting somatic variants from amplicon sequencing data. Low-
quality reads were not filtered out before alignment: after alignment, quality values 
(i.e. Phred scores) were used to exlude error bases with low quality from further 
analysis. First, previously reported STAT3/5b mutations were verified in all STAT-
mapped amplicons: all variants with variant allele count over 5 and variant allele 
frequency (VAF) over 0.5% were taken into consideration. Second, all variants with 
variant allele count over 5 and VAF over 0.5% were called from STAT-mapped 
amplicons. From these candidates false positives were initially filtered out based on 
the noise (estimated error rate) level from control sample in every run making use of a 
binomial distribution to compute p-value for the event that more than the frequency of 
alternative alleles were observed when the null hypothesis is true. However, variants 
with VAF over 2% were called independent of the noise. A specific frequency ratio 
was used to filter out false positive by dividing the ratio of variant calls/number of all 
the bases (at a position) by the ratio of variant allele quality sum/quality sum of all the 
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bases. All samples with a frequency ratio ≥0.90 were considered to be true mutations, 
and the variants from both scripts with a borderline frequency ratio between 0.85-0.89 
were verified with IGV.  
12.3. RNA sequencing analysis  
RNA sequencing reads from the patient and healthy control samples were aligned 
using TopHat145 and TopHat2146 to the human genome reference hg19. Mapped reads 
were counted with the HTSeq Python package147. To analyze the differentially 
expressed genes between samples DESeq2 (R/Bioconductor) was used148. Results 
were visualized with Ingenuity Pathway Analysis (IPA) software.  
13. Microarray expression analysis 
 
In study I, RNA was extracted from CD8+ cells from STAT-mutation negative as 
well as STAT3-mutated LGL-patients. In study IV, RNA was extracted from PLL 
patients CD4+ cells. Anonymous Red Cross buffy coat CD4+, CD8+ and NK RNA 
were used as biological replicates and controls in the experiment. Microarray analysis 
was performed using the Illumina Human HT-12 v4 BeadChip expression array 
which targets >47000 probes in the human genome (cover content from NCBU 
RefSeq Release 38 and legacy UniGene content). The data was read with an iScan 
instrument (Illumina) and primary analysis was done with Genome Studio software 
v2011.1 (Illumina). The results were normalized and log2-transformed with the 
Chipster open source platform149. In order to determine the similarity of the 
expression profiles a distance dendrogram was constructed using Pearson correlation 
and the average linkage method. Differentially expressed genes were filtered from the 
data using the empirical Bayes test with p-value cut-off of 0.05. Microarray data are 
available in the ArrayExpress database (www.ebi.ac.uk/arrayexpress). 
14. Drug sensitivity and resistance testing (DSRT)  
14.1. Inhibitors 
The oncology compound collection included 306 drugs consisting of commercially 
available approved, investigational and experimental anti-cancer compounds. Drug 
classes included in the collection were apoptotic modulators, conventional 
therapeutics, epigenetic modifiers, hormone therapies, HSP inhibitors, immuno-
modulatory agents, kinase inhibitors, kinesin inhibitors, metabolic modifiers and 
rapalogs. Compounds were acquired from National Cancer Institute Drug Testing 
Program or purchased from Active Biochem, Axon Medchem, Cayman Chemical 
Company, ChemieTek, Enzo Life Sciences, LC Laboratories, Santa Cruz 
Biotechnology, Selleck, Sequoia Research Products, Sigma-Aldrich and Tocris 
Biosciences.  
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14.2. The platform 
DSRT was performed on fresh or viably frozen MNC samples from T-PLL patients 
and healthy controls in study IV. The compounds were dissolved in DMSO and 
preprinted on 384-well plates (Corning) using Echo 550, an acoustic liquid handling 
device (Labcyte Inc.). Each drug was plated in five concentrations covering a 10,000-
fold concentration range. The drug plates were stored in pressurized StoragePods 
(Roylan Developments Ltd.) before use. The compounds were dissolved in a shaker 
with 5 µl of Mononuclear cell media (MCM) for 10 minutes. 20 µl of single-cell 
suspension (equivalent to 10,000 cells) was transferred to each well using a 
MultiDrop Combi (Thermo Scientific) dispenser. The plates were incubated 37°C and 
5% CO2, and after 72 hours the cell viability was measured using CellTiter-Glo 
luminescent assay (Promega) and a Pherastar plate reader (Fig 7). The data were 
normalized to negative control wells (DMSO only) and positive control wells 
containing 100 µmol/L benzethonium chloride (BzCl).  
 
 
Figure 7. Workflow of drug sensitivity and resistance testing platform and analysis using Breeze. 
14.3 Drug sensitivity analysis 
Percentage of survival was calculated with Dotmatics Browser/Studies software and 
an in-house developed interface, Breeze, was used to analyze the data. To assess 
quantitative drug response a drug sensitivity score (DSS) was calculated based on the 
dose-response curves. DSS is an integrative and robust drug response model based on 
the normalized area under the curve by taking all four curve fitting parameters into 
account150. The possible range of DSS scores is between 0-50. Furthermore, selective 
drug sensitivity scores (sDSS), representing leukemia-specific responses, were 
calculated by comparing the DSS score from patient samples to the median values of 
healthy donors. Drugs with sDSS values above 5 were considered selective and above 
10 highly selective to the cell sample tested. The DSS-based analysis platform is 
freely available as an R-package at: https://dss-calculation.googlecode.com/svn/trunk/ 
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14.4. Target addiction score (TAS) 
To elucidate the pathways that are active in T-PLL and to quantify the functional 
sensitivity of the samples to therapeutic targets, the target addiction score (TAS) was 
calculated for 12 samples for which drug response and microarray expression data 
was available. TAS quantifies the functional sensitivity of the samples to therapeutic 
targets150. The TAS algorithm integrates the DSS profiles with global compound-
target interaction networks to estimate the level of addiction of each patient sample to 
the on- and off-targets of the targeted compounds in the drug screening library. 
Specifically, for a given drug target t, TAS was computed as an average of the DSS 
value over those inhibitors that target the protein t. The targets for TAS analysis were 
selected based on KIBA score of 3 and for drugs which had no targets with this 
criteria then the KIBA score of 4 were applied151. The total numbers of targets with 
above criteria were 614 target proteins for 243 drugs. 
15. Functional assays 
15.1. Mutagenesis and luciferase reporter assays 
To explore the functional effects of STAT3 and STAT5B mutations in study II and III, 
expression constructs were generated with the identified variants in either pDEST40 
containing STAT3 or pCMV6-XL6 containing STAT5B. Mutagenesis PCR was 
performed according to instructions (Geneart® Site-Directed Mutagenesis system, 
Invitrogen) with mutagenesis primers ordered from Sigma (Table 5).  
 
Table 5. STAT3 and STAT5B mutagenesis primers 
 
 
For STAT3 mutations, HEK-293 cells stably expressing a STAT3 firefly luciferase 
reporter (HEK293 Gloresponse SIE Luc2P Hygro cells, Promega) were grown in 
Dulbecco's Modified Eagle Medium (DMEM) + 10% FBS+ 200µg/ml Hygromycin B 
(Life Technologies). For STAT5B mutations, Hela cells co-transfected with the 
STAT5B luciferase reporter pGL4.52 (Luc2P/STAT5RE/Hygro) were used. The cells 
were plated in 96-well plates with 10000 cells/well the day before the luciferase 
readout. Transfection with the constructs was carried out 6h after plating using 
Fugene®HD transfection reagent (Fugene:DNA ratio 3.5:1, Promega). The next day, 
the HEK-293 cells were starved in DMEM+ 1% FBS for 3h, followed by stimulation 
with IL-6 (100ng/ml) for 3h. Luciferase activity was determined with Dual-Glo™ 
Luciferase Assay System (Promega) according to instructions. 
In study IV, Jurkat cells containg a nuclear factor of activated T-cells (NFAT) 
luciferase reporter (Signosis) were cultured in RPMI1640 + 10% FBS + 2 mM L-
glutamine + penicillin and streptomycin. 20,000 cells per well were incubated with 
Primer&target Forward Reverse Study
STAT3%F174S CCAGGATGACTTTGATTCCAACTATAAAACCCTCAA TTGAGGGTTTTATAGTTGGAATCAAAGTCATCCTGG
STAT3%H410R GCCTCTCTGCAGAATTCAAACGCTTGACCCTGAGGGAGCAGAG CTCTGCTCCCTCAGGGTCAAGCGTTTGAATTCTGCAGAGAGGC
STAT3%Y640F CTGAACAACATGTCATTTGCTG CTGCTGCTTTGTGAATGGTTCCACGG
STAT5b%Q706L GTGAAGCCACAGATCAAGCTAGTGGTCCCTGAGTTTGTGA TCACAAACTCAGGGACCACTAGCTTGATCTGTGGCTTCAC
STAT5b%S715F GAGTTTGTGAACGCATTTGCAGATGCCGGGGGC GCCCCCGGCATCTGCAAATGCGTTCACAAACTC
STAT5b%N642H GAAAGAATGTTTTGGCATCTGATGCCTTTTAC AAAGGCATCAGATGCCAAAACATTCTTTTC
II
III
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the indicated concentrations of SNS-032 on a 384-well plate for 5 hours in the 
presence of 0.5 µg/ml purified anti-CD3 (clone UCHT1) and 0.5 µg/ml purified anti-
CD28 (clone L293) antibodies (BD Biosciences) with 4 µg/ml goat anti-mouse IgG 
secondary antibody (ThermoFischer Scientific). At the end of the incubation, ONE-
Glo reagent (Promega) was added at a 1:1 ratio to the cell culture medium and 
luminescence reads were measured by a Pherastar FS. Luminescence reads were 
normalized to reads from wells with DMSO (negative control) and BzCl (positive 
control) to generate percent inhibition values.  
15.2. Western blotting 
To investigate the phosphorylation status of the variants, HEK-293 and Hela cells 
transfected with the variants were analyzed by Western blot with either a phospho 
STAT3 (Cell Signaling, 9131S) or a phospho STAT5 (Cell Signaling, 9314) specific 
antibody. Protein lysates of the different variants were separated with polyacrylamide 
gel electrophoresis on a 12% SDS-PAGE gel and transferred to a nitrocellulose 
membrane. The membrane was blocked with PBS+ 5% BSA or PBS+ 5% fat free 
milk containing 0.1% Tween 20. The membrane was subsequently incubated with 
primary antibodies, which consisted of rabbit anti-pSTAT3 1:1000 or rabbit anti-
pSTAT5 antibody 1:1000 in PBS+ 5% BSA as well as mouse anti-beta actin 1:5000 
(Abcam, AC-15) in PBS+ 5% milk as a loading control. Goat anti-rabbit IRDye 800 
(Li-cor Odyssey 926-32211) and goat anti-mouse IRDye 680 (Li-cor Odyssey 926-
68020) 1:20000 were used as secondary antibodies. The proteins were visualized with 
the Li-cor Odyssey Infrared Imaging system and the intensity of the pSTAT3/5 bands 
were normalized against STAT3/5 to compensate for the differences in transfection 
efficacy of the wt and variants. 
15.3. Immunohistochemistry  
Immunohistochemical staining with pSTAT3 and CD57 antibodies was performed 
with Leica BOND-MAX autostainer (Leica Microsystems) to detect the infiltration of 
LGL cells (CD57 staining) and phosphorylation of STAT3 (pSTAT3 staining). 
Paraffin sections from 5 LGL leukemia patients and 2 healthy control bone marrow 
(BM) biopsies were processed with Bond Polymer Refine Detection kit (Leica 
Microsystems) using citrate buffer for antigen retrieval. Staining was done with a 
STAT3 Tyr 705 antibody (9145L, Cell Signaling Technology) diluted 1:100 or a 
CD57 antibody (TB01, Dako) diluted 1:100. 
 The slides were analyzed with the Zeiss Axio Imager AX10 microscope and 
photographed with Nuance FX multispectral tissue imaging system (420-720nm). The 
pictures were managed and prepared with Nuance 3.0.0 	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16. Statistical methods 
 
For the luciferase reporter assays in study II and III statistical comparisons between 
the variants were performed with one-way ANOVA and the Dunn’s multiple 
comparison test. A P value <0.05 was considered statistically significant. 
In study IV, correlation of the drug sensitivity profiles across all T-PLL 
patients was performed using the Spearman and Euclidean distance measures of the 
drug and sample profiles, respectively. Weak drugs (mean DSS<5) were excluded 
from the analysis.	  Hierarchical, complete linkage clustering was performed with 
Cluster 3.0152 and visualized in Java Tree View (v1.1)153.  
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Results  
17. Characterization of STAT-mutation negative LGL patients (I) 
 
To elucidate what other molecular factors are driving the pathogenesis of LGL 
leukemia, STAT-mutation negative patients were selected for exome sequencing and 
gene expression analysis. The chosen patients fulfilled the WHO 2008 diagnostic 
criteria for LGL leukemia.  
17.1. Exome sequencing results of STAT-mutation negative patients 
Three patients previously found not to carry STAT3 or STAT5 mutations were sent for 
exome sequencing. All patients had T-LGLL with a CD3+CD8+CD57+TCRαβ+ 
phenotype and harbored a CD8+ monoclonal expansion, which was detected by TCR 
Vβ analysis. Two of the patients harbored a major clonal expansion (73% and 89% of 
CD8+ cells), while one patient had a smaller expansion (28%). No clonal expansions 
were detected using the TCR Vβ analysis of the CD4+ lymphocytes. All three patients 
were diagnosed with T-LGLL at an advanced age (> 60 years). Concomitant 
neutropenia was seen in patients 1 and 2, and the latter also suffered from anemia and 
monoclonal gammopathy of unknown significance. Patient 3 had no concomitant 
disorders (Table 6). 
 
Table 6. Clinical characteristics of the exome sequenced STAT-mutation negative 
patients 
Patient	  
LGL	  leukemia	  
type	   Sex	  
Age	  
at	  dg	  
(y)	  
WBC	  count	  
at	  dg	  
(10E9/L)	  
Lymph	  
count	  at	  dg	  
(10E9/L)	  
Lymph	  
count1	  
(10E9/L)	  
CD8+	  
Vbeta2	  
Concomitant	  
disorders	   Therapy	  
1	  	  
CD3+CD8+	  
CD57+TCRαβ	   F	   70	   7.7	   6.4	   3.9	  
Vb.7.1:	  
28.2%	  
Neutropenia,	  
BM	  
eosinophilia	  
Neutropenia:	  
G-­‐CSF	  
2	  	  
CD3+CD8+	  
CD57+TCRαβ	   M	   76	   10.8	   9.40	   5.8	  
Vb.20:	  
73%	  
MGUS,	  
neutropenia,	  
anemia	   No	  treatment	  
3	  	  
CD3+CD8+	  
CD57+TCRαβ	   M	   60	   11.1	   3.7	   3.8	  
Vb.3:	  
89.3%	   no	  	   No	  treatment	  
Abbreviations: M, male; F, female; y, years; WBC, white blood cell; dg, diagnosis; BM, bone marrow; MGUS, 
monoclonal gammopathy of unknown significance; G-CSF, granulocyte-colony stimulating factor. 
1 Lymphocyte count at the time of sample preparation; 2 Proportion of Vbeta clone in CD8+ cells of the sample 
 
The exome sequencing of CD8+ (tumor) and CD4+ (healthy) cells yielded on average  
53,184,000 paired reads that mapped to the reference genome. The median coverage 
was not analyzed, but 55–60% of the target exons were sequenced with more than 20-
fold coverage. On average, the patients had 11 non-synonymous mutation calls with 
high-confidence somatic p-values (< 0.01). The bioinformatics pipeline identified 
deleterious mutations expected to impact protein function based on conservation 
scores and PolyPhen predictions. Based on somatic p-values and medical relevance, 
variants were chosen for validation by PCR (Table 7). 
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Table 7. Somatic mutations identified by exome sequencing in STAT-mutation 
negative LGL-leukemia patients and validated by capillary sequencing 
 
Abbreviations: Chr, chromosome; Var, variant; Ref, reference; NA, not available. 
1 Somatic p-value for somatic/LOH-events 
2 Rejected-substitution score describing the conservation of the amino acid from the program 
 
The protein tyrosine phosphatase receptor T (PTPRT) was found to be mutated in 
patient 1 with a variant frequency of 14%. As the patient harbored a 28% clone in the 
leukemic CD8+ fraction, the mutation is presumed to be heterozygous. The tumor 
suppressor gene PTPRT is known to mediate STAT3 deactivation through the 
reversal of Tyr705 phosphorylation on STAT370. This novel V995M mutation 
converts a highly conserved hydrophobic valine residue into methionine. The 
mutation occurs in the cytoplasmic part of PTPRT, within the tyrosine-protein 
phosphatase 1 domain that is actively responsible for the phosphatase activity (Fig 8). 
This PTPRT mutation could therefore affect the activation of STAT3 by reducing the 
dephosphorylation of Tyr705, leading to an increase in the expression of STAT3 
target genes. 
 
 
Figure 8. Schematic representation of the location of the V995M mutation in PTPRT from Polyphen2. 
The mutation is located in the catalytically active tyrosine-protein phosphatase 1 domain that is 
responsible for the phosphatase activity of PTPRT. 
 
 
 
Patient Gene Chr Chr.,position Mutation,type Transcript,ID
Ref.,
base
Var.,
base
Site,
coverage
Tumor,
variant,
freq. Protein
Somatic,p@
value1
1 PTPRT 20 40743955 Missense NM_133170 C T 92 14% V995M 0,000604
2 BCL11b 14 99723858 Missense NM_022898.1 T C 43 51% H126R 1,45>07
RAD21 8 117868903 Missense NM_006265.2 C T 59 27% E266K 2,45>05
3 SLIT2 4 20543120 stop>gained NM_004787.1 G A 42 55% W674stop 6,62>09
NRP1 10 33510758 Missense NM_001024628.2 C T 43 37% V391M 1,40>07
	   45	  
Through exome sequencing, an H126R mutation in the BCL11B gene was revealed in 
the leukemic cells of patient 2 at a VAF of 51%. BCL11B is essential for T-cell 
survival, and its overexpression can lead to an increase in T-cell activation and 
proliferation154. In hematopoietic lineages, BCL11B expression is restricted mainly to 
T-cells and plays a key role in both the maintenance of T-cell identity and T-cell 
development155. Patient 2 also had a missense mutation in the gene RAD21 (E266K), 
which mediates the repair of DNA double-strand breaks and plays a role in chromatid 
cohesion during mitosis. Furthermore, the deletion of RAD21 in mouse thymocytes 
leads to defective chromatin architecture at the TCRα locus and limited differentiation 
potential156. 
The exome sequencing of the CD8+ LGL cells of patient 3 revealed a SLIT2 
mutation (W674stop) with a variant frequency of 54%. The mutation is located within 
a cysteine-rich domain bordering an LRR-domain, hypothesized to mediate protein-
protein interactions. SLIT2 is a secreted glycoprotein that possesses anti-
inflammatory properties and is, for example, able to modulate CXCR4-mediated 
functional effects in T-cells157. Another mutation, V391M in neuropilin 1 (NRP1), 
was detected with a VAF of 37% in the patient’s leukemic sample. The mutation site 
is highly conserved and located within the discoidin domain, a major domain of many 
blood coagulation factors. NRP1 was originally known as a receptor for the 
semaphorin 3 subfamily, mediating axonal growth and neuronal guidance. NRP1 also 
mediates interactions between dendritic cells (DCs) and T-cells that are essential for 
the initiation of the primary immune response158.  
To validate the findings, the mutation sites of PTPRT, BCL11b, SLIT2 RAD21, 
and NRP1 were screened with Sanger sequencing in a larger cohort of STAT-
mutation negative LGL leukemia patients (n=113). No additional patients were found 
to have mutations at the targeted sites. 
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17.2 Gene expression analysis of STAT-mutation negative LGL-patients 
Microarray gene expression analysis was performed with CD8+ RNA from three 
STAT-mutation negative patients and two patients with known STAT3 mutations. 
CD4+, CD8+, and NK cell fractions from healthy controls were used as biological 
replicates. In the distance dendrogram based on the gene expression profile (Fig 9), 
healthy CD4+, CD8+ and NK fractions clustered together, whereas LGL-leukemia 
patients formed a separate cluster. In the T-LGLL cluster, patients were situated 
independently of STAT-mutation status, suggesting that the expression profiles are 
quite similar. This was further emphasized when comparing the gene expression 
between T-LGLL patients with or without STAT3 mutation: no genes were 
significantly over- or underexpressed.  
 
 
 
Figure 9. Dendrogram visualizing the clustering of LGL leukemia patients and healthy controls based 
on their gene expression profiles. 
 
 
!
!NK!!!!!!!!NK!!!!!!!!CD4!!!!!!!CD4!!!!!!!CD8!!!!!!!CD8!!!!!!!CD8!!!!!!CD8!!STAT3!!
mutated!!
LGL!pa5ent!
STAT3!!
mutated!
LGL!pa5ent!
Pa5ent!1! Pa5ent!2! Pa5ent!3!
	   47	  
A comparison between all 5 T-LGLL patients and the CD8+ healthy controls 
revealed 39 genes to be differentially expressed (Fig 10). FGR, a member of the Src 
family of kinases, was 3-fold overexpressed in the T-LGLL patients when compared 
to healthy controls. It has been shown that FGR can phosphorylate STAT3, thereby 
activating the STAT3 pathway159. FGR is also activated by BCR-ABL in B-cells of 
B-ALL patients160. The transmembrane receptor SLAMF6, which mediates important 
regulatory signals between immune cells, was also 3-fold overexpressed in T-LGLL 
patients. SLAMF6 appears to co-stimulate particularly CD8+ and CD4-CD8- T-cells, 
while SLAM signaling has also been shown to be involved in the pathogenesis of 
autoimmune diseases, including systemic lupus erythematosus161. Interestingly, tumor 
necrosis factor (TNF) was expressed at a 2-fold lower level in T-LGLL patients when 
compared to healthy CD8+ cells.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Heatmap representing the gene expression profiles of 3 patients without STAT- mutations, 2 
STAT3-mutated patients, and 4 healthy controls (CD8+). A total of 39 genes were differentially 
expressed when comparing all T-LGLL patients to the healthy controls (p < 0.05, fold change ranging 
from 2.7 to -2.5).  
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17.3. STAT3 activation in STAT-mutation negative patients 
BM-biopsy samples from healthy controls and T-LGLL patients with different 
mutational status were studied with immunohistochemical staining of CD57 and 
pSTAT3 expression (Fig 11). LGL cells typically express CD57 on their surface, and 
IHC staining showed that BM-samples from LGL leukemia patients were infiltrated 
with CD57-expressing LGL-cells, while no such infiltration was observed in healthy 
control samples. Both the STAT-mutated and STAT-negative patients presented with 
positive pSTAT3-staining in the infiltrated lymphocytes, indicating STAT3 
activation. No pSTAT3 was observed in the healthy control BM-samples. 
 
 
 
 
Figure 11. BM-biopsy samples from a healthy control and three LGL-leukemia patients stained with 
CD57 and pSTAT3 antibodies (patients 1 and 2 without STAT-mutations). No staining was observed in 
the healthy control, while the leukemic samples showed the infiltration of lymphocytes positive for 
CD57 and pSTAT3 (magnification, 63x).  
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18. STAT3 and STAT5B mutations outside the SH2-domain in LGL-leukemia 
(II–III)  
 
During the exome sequencing of additional STAT-mutation negative T-LGLL 
patients, STAT3 and STAT5B mutations were found outside the hotspot SH2-domain 
covered by our custom STAT hotspot amplicon system. This led to the further 
screening of the entire STAT3 gene and the STAT5B transactivation domain in a larger 
cohort of patients to elucidate whether mutations outside the SH2-domain are frequent 
in LGL-leukemia. 
18.1. Somatic mutations in the coiled-coil and DNA-binding domain of STAT3 in 
LGL-leukemia (II) 
To discover novel genetic markers, seven T-LGLL patients who were previously 
negative for STAT3- or STAT5-mutations in the SH2-domain were selected for exome 
sequencing. Patient 1 harbored a heterozygous missense mutation H410R in the 
DNA-binding domain. The VAF was 49% in the CD8+ fraction, which consisted of 
one major clone (vb.17: 95%) according to the TCR Vβ results (Table 8).  
As the mutation spectrum outside the SH2-domain hotspot in STAT3 has not 
previously been explored systematically, we developed a targeted deep amplicon 
sequencing platform that allows for the sensitive analysis of all the exons of the 
STAT3 gene. Using this system, we sequenced MNC samples from 99 T-LGLL 
patients previously confirmed to be STAT3 hotspot mutation negative. From these, 
three additional patients were discovered to have STAT3 missense mutations outside 
of the SH2-domain (Table 8 and Fig 12). Patient 2 exhibited the same H410R 
mutation seen in the DNA-binding domain (MNC VAF: 8.8%), and patient 3 had a 
S381Y mutation (MNC VAF 7%). Patient 4 had a novel F174S mutation (VAF 54% 
in CD8+ cells) in the coiled-coil domain of STAT3. The clinical phenotype of 
patients carrying STAT3 DNA-binding and coiled-coil domain mutations did not 
differ from other typical LGL leukemia cases. The frequency of STAT3 mutations was 
3.8% (4 of 106 patients) in patients with no previously detected hotspot mutations in 
STAT3 or STAT5. 
 
Table 8. Clinical characteristics of the patients with STAT3 mutations outside the 
SH2-domain 
 
Abbreviations: M, male; F, female; VAF, variant allele frequency; Hb, hemoglobin; Leuk, leukocytes; Lymph, 
lymphocytes; Neut, neutrophils; Trom, thrombocytes. 
 
	  
Exome&
sequencing Mutation VAF Sex
Age&at&
diagnosis
Hb&
(g/L)
Leuk&
(10^9/L
Lymph&
(10^9/L)
Neut&
(10^9/L)
Trom&
(10^9/L) Vbeta Concominant&disorders
Patient'1 H410R 49%'CD8+ M 60 85 10.2 1.6 1.4 203 vb.17:'97%
Anemia,'neutropenia,''''''''''
BEcell'dyscracia,'
hypergammaglobulinemia
Amplicon&
sequencing
Patient'2 H410R 9%'MNC F 75 127 4.2 3.7 0.0 260 NA Neutropenia
Patient'3' S381Y 7%'MNC F 20 108 7 4.7 2 181 NA Anemia
Patient'4 F174S 54%'CD8+ M 68 95 8.6 7.2 1.1 211 NA Anemia,'neutropenia
	   50	  
 
 
Figure 12. Location of novel mutations in the coiled-coil alpha domain and DNA-binding domain in 
addition to the previously described SH2 domain mutations in STAT3. 
18.2 Somatic STAT5B mutations in CD4+ T-cell large granular lymphocyte 
leukemia (III) 
CD4+ T-LGL leukemia is a rare and poorly described disease entity. Through the 
exome sequencing of three such patients, we were able to identify somatic mutations 
in the transactivation domain of STAT5B in two CD4+ T-LGLL patients. Patient 1 
had a Q706L mutation at a VAF of 45% in the CD4+CD8+ tumor fraction. Patient 2 
displayed an S715F mutation (VAF 36%) in the CD4+ fraction (Fig 13). This 
mutation is located in a serine phosphorylation site in the transactivation domain.  
 
 
Figure 13. Linear representation of the STAT5B protein structure and mutations found in CD4+ LGL 
patients (blue and green boxes). Red represents multiple known tyrosine and serine phosphorylation 
sites. 
 
To elucidate whether STAT5B mutations are more prevalent in CD4+ LGLL cases, 
deep amplicon sequencing was used for the screening of the SH2 and transactivation 
domains of STAT5B in CD4+ (n=8), STAT3-mutated CD8+ (n=37), and non-mutated 
CD8+ (n=58) T-LGLL patients. Additionally, the same regions were screened with 
Sanger sequencing in Japanese and Chinese LGL-leukemia cohorts consisting of 
CD8+ and CLPD-NK cases (n=57). None of the patients with CD8+ T-LGLL or 
CLPD-NK had STAT5B mutations. In contrast, 4 of 8 CD4+ T-LGLL cases had 
STAT5B mutations. Of the four patients with STAT5B mutations, three possessed the 
earlier described N642H mutation and one the Y665F mutation. Altogether, the 
STAT5B mutation frequency in CD4+ T-LGLL patients in our cohort was 55% (6/11 
patients). This is significantly higher than in the previous study (2%) of 211 CD8+ T- 
and NK-cell LGL-leukemia cases where STAT5B SH2 domain mutations were 
initially discovered19. 
Contrary to other more aggressive T-cell malignancies with STAT5B 
mutations, the disease courses of our 6 STAT5B-mutated patients were indolent, and 
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none of the patients needed treatment during the observation time (median follow-up 
4 years). Two patients showed neutropenia, but anemia was not noted (Table 9). In 
our cohort, none of the 11 cases with CD4+ T-LGLL suffered from RA although it is 
commonly associated with CD8+ T-LGLL. All STAT5B-mutated CD4+ T-LGL cases 
possessed a TCRαβ+CD16-CD56+CD57+ T-cell phenotype in accordance with the 
earlier reports162,163,164. Interestingly, all STAT5B-mutated patients had mutation VAFs 
corresponding to large monoclonal expansions, while significant proportions of 
STAT3 mutations in CD8+ T-LGL leukemia and CLPD-NK are detected in small 
subclones.  
 
Table 9. Clinical features of STAT5B-mutated CD4+ T-LGLL patients 
	  
 
Abbreviations: VAF, variant allele frequency; M, male; F, female; WBC, white blood cell; LGL, large granular 
lymphocyte; Hb, hemoglobin. 
Neutrophil and LGL percentage from whole white blood cell population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Q706L  S715F N642H N642H Y665F N642H 
(45% VAF) (36% VAF) (25% VAF) (46% VAF) (31% VAF) (27% VAF)
Age (years) 61 70 74 79 82 66
Sex M F M F M M
WBC count 
(10^9/L) 8.5  10.2 9.0 8.7 13.9 9.4
Neutrophil 
(%) 40   16 12 5 51 32
LGL (%) 52 72 71 91 39 63
Hb (g/L) 134 124 119 126 155 141
Platelets 
(10^9/L) 399 204 144 186 245 265
Complications diabetes none none gastrointestinal hemorrhage  none lung cancer
Observation 
periods 5 years 7 years 14years 6months 3years 2years
Outcome alive alive death alive alive alive
STAT5b 
mutation
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18.3. Functional studies with mutated STAT3/5b (II–III) 
To explore the functional implications of the novel STAT3 and STAT5B mutations, we 
generated expression constructs for WT and a variant STAT3/STAT5B protein and 
transfected appropriate cell lines containing reporters. Luciferase measurements of 
SIE-reporter HEK-293 cells transfected with these constructs revealed transcriptional 
activation, while the phosphorylation status of STAT3 and STAT5 was investigated 
with protein lysates in western blots. 
In HEK-293 cells, a noticeable increase in both basal and IL6-stimulated 
transcriptional STAT3 activation was induced by the coiled-coil domain F174S and 
DNA-binding domain H410R variants compared to WT STAT3 (Fig 14A). The 
S381Y variant, on the other hand, did not show a similar increase. The 
phosphorylation status of the variants revealed F174S and H410R to induce a 
phosphorylation pattern comparable to the known activating Y640F SH2-domain 
mutation (Fig 14B). However, the S381Y variant did not seem to be highly 
phosphorylated, as the level of pSTAT3 was similar to that seen with the WT STAT3. 
Furthermore, the expression levels of six known STAT3 target genes were measured 
by qPCR, and SOCS3, CCL2, JUNB, and BCL3 were revealed to be upregulated by 
the F174S, H410R, and Y640F mutations but not by the S381Y variant when 
compared to the WT (Fig 14C).  
A.      B. 
       
	  
C. 
 	   
 
 
 
 
 
 
 
 
 
Figure 14. A. STAT3 reporter assay results. Each condition was tested in triplicate, and the statistical 
significance was calculated with a one-way ANOVA (*=p<0.05, **=p<0.001, error bars representing 
SD). B. Western blotting results of the phosphorylation of STAT3. β-actin was used as a loading 
control. C. Expression levels of six known STAT3 target genes were measured with qPCR All reactions 
were run in triplicate wells, and gene expression was quantified using the delta-delta Cq method. 
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In HeLa cells transfected with the STAT5B constructs, the mutated STAT5B S715F 
construct significantly enhanced the transcription of the co-transfected STAT5 
reporter (18-fold compared to WT STAT5B) similar to the N642H mutation (Fig 
15A), while the Q706L mutation activation was equal to the WT. With the western 
blot analysis, the S715F and N642H mutations showed significantly increased 
phosphorylation when compared to the WT STAT5B (Fig 15B) in accordance with 
their activating nature. 
 
 
A.        
 
 
Figure 15. A. STAT5B reporter assay results The experiment was repeated three times. Columns 
present mean of the fold-change activity. Error bars indicate the standard error of the mean (S.E.M.). 
B. Western blotting results of the phosphorylation of STAT5B. β-actin was used as a loading control. 
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19. Discovery of novel drug sensitivities in T-PLL by ex vivo drug testing and 
genetic profiling (IV) 
 
To find novel therapeutic options for the highly aggressive T-cell malignancy T-PLL, 
we applied ex vivo drug sensitivity testing to 39 patient samples. In addition, in an 
effort to molecularly profile the disease and find potential biomarkers for treatment, a 
larger cohort of T-PLL patients (n=70) underwent targeted JAK/STAT amplicon 
sequencing. Gene expression analysis was also applied to a smaller cohort (n=12) to 
find pathways addicted to certain drugs (Fig 16). 
 
 
Figure 16. Study design with relevant patient numbers. 
19.1. Targeted deep sequencing of the JAK/STAT pathway in T-PLL 
Deep targeted amplicon sequencing of known recurrent genetic variants in the genes 
STAT5B, JAK1, and JAK3 was performed with the Illumina MiSeq platform.	  The 
K315E mutation hotspot in IL2RG was screened with Sanger sequencing (see Table 3 
for primer sequences).  
The targeted amplicon sequencing revealed that 69% of the T-PLL patient 
samples (48/70) harbored one or several mutations in genes involved in the 
JAK/STAT pathway (JAK1, JAK3, STAT5B, or IL2RG; Figs 17 and 18). Single JAK3 
mutations were seen in 29% of T-PLL patients, and the most prevalent of these 
mutations was the M511I missense mutation located in the linker between the SH2 
and the pseudokinase domain (37% of all patients). STAT5B mutations were seen in 
7% of the patients, while 6% harbored single JAK1 mutations, and 1% of the cases 
were IL2RG-mutated alone. Twenty-six percent of the patients harbored more than 
one mutation in the JAK-STAT pathway. The VAF of these mutations ranged from 
1% to 87% in the MNC samples, with 38/48 (79%) of the mutated cases showing 
mutations with a frequency above 10%. Interestingly, clonal STAT5B mutations 
(9/70) did not coexist with any clonal JAK mutations in our cohort. In patients with 
multiple mutations, subclonal mutations were commonly observed.  
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Figure 17. Targeted amplicon sequencing was performed on the mutation hotspots in the genes JAK1, 
JAK3, STAT5B, and IL2RG. Based on this targeted sequencing, 69% of T-PLL patients harbor one or 
multiple mutations of the JAK/STAT pathway.  
 
 
 
 
Figure 18. Linear 2D model of JAK1, JAK3, and STAT5B with the positions of the mutations detected 
with deep amplicon sequencing. In IL2RG, only the K315E mutation hotspot was sequenced (not 
shown). 
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19.2. Clustering of drug sensitivity profiles to reveal selective sensitivities 
By calculating the mean of the DSS values for all T-PLL patients screened and 
comparing them with the median of the healthy controls, we ranked the drugs by their 
leukemia-specific effect on T-PLL samples. Based on DSRT analysis, the drug with 
the highest average sDSS score was the CDK inhibitor SNS-032 followed by the p53 
re-activator Prima-1 and BCL inhibitors navitoclax and ABT-199 (Fig 19A). The 
CDK inhibitor SNS-032 is highly effective in killing cells in MNC samples from T-
PLL but also in healthy PB. The p53 re-activator Prima-1 Met, on the other hand, has 
a more T-PLL-specific profile when compared to other leukemias and healthy control 
MNCs (Fig 19B).  
 
A.        B.  
 
      
 	  	  
 
Figure 19. A. Top 20 most effective drugs for T-PLL patients (n=39) based on the median of sDSS 
scores where the DSS scores have been compared with DSS from 4 healthy subjects. Drugs with 
median sDSS values above 5 are considered selective to the cell samples tested. B. Comparison 
between DSS scores of specific drugs for different leukemias and healthy controls.  
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Next, we performed a drug-drug correlation of the DSS scores of all T-PLL 
patients to reveal effective drug groups, and PI3K/AKT/mTOR, HSP90, and HDAC 
inhibitors stood out as the most effective substances. The clustering of the patients’ 
sDSS scores for these substances showed a division of samples into 3 main drug-
response groups: sensitive, only sensitive to HDAC inhibitors, and resistant groups 
(Fig 20). Strikingly, the presence of JAK/STAT mutations, TCL1A translocations, or 
ATM deletion status did not predict responses to any specific substance class.	  
 
 
 
      Resistant          HDAC inhibitor sensitive              Sensitive 
 
Figure 20. Clustering of the sDSS values of the T-PLL patients was performed using unsupervised 
hierarchical complete-linkage clustering using Spearman and Euclidean distance measures of the drug 
and sample profiles.	  Hierarchical clustering was performed with Cluster 3.0 and visualized by Java 
Tree View. 
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19.3. Linking drug responses to genetic profiles 
The recurrent mutations in the JAK/STAT signaling elements implicate a new 
actionable lesion to be explored in T-PLL. A closer inspection of the JAK inhibitors 
ruxolitinib (JAK1/2) and tofacitinib (JAK1/3) showed that patient samples were on 
average more sensitive to ruxolitinib (Fig 21). However, drug responses to JAK 
inhibitors did not link to the presence of recurrent genetic aberrations in the 
JAK/STAT pathway. In the majority of patients with JAK3 mutations, ruxolitinib was 
effective, but there were also notable exceptions. Interestingly, among the patient 
samples with practically no sensitivity to ruxolitinib or tofacitinib, there were two 
STAT5B-mutated patients with the highly activating N642H variant. 
 
 
 
Figure 21. Drug sensitivity of T-PLL patients to JAK inhibitors ruxolitinib (JAK1/2) and tofacitinib 
(JAK1/3). Treatment ranges were 0.001–10 µM for ruxolitinib and 0.0005–5 µM for tofacitinib. 
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19.4. Network analysis reveals active pathways 
To elucidate which pathways are active in PLL and which target genes are acted upon 
by certain drugs, a target addiction score (TAS) was calculated for 12 samples for 
which drug response and microarray expression data were available. The analysis 
revealed 145 addicted genes and highlighted genes related to histone deacetylation 
and cell cycle regulation (Fig 22), further supporting the use of HDAC and CDK 
inhibitors in T-PLL. The TAS scores and differential gene expression values were 
also used to analyze canonical pathways in Biocarta (Fig 23A). In two patients, the 
retinoblastoma (RB) pathway, related to checkpoint signaling in response to DNA 
damage, was upregulated when compared to healthy controls. In normal 
circumstances, the ATM protein kinase detects DNA damage and, in response to this, 
activates DNA repair factors and inhibits cell cycle progression. However, in T-PLL, 
ATM is frequently dysfunctional, leading to progression to S-phase despite defects in 
the genome. Compounds such as p53 activators, CDK inhibitors, and HDAC 
inhibitors are able to affect this pathway (Fig 23B). 
 
 
 
Figure 22. TAS heatmaps based on microarray expression data and DSRT data of 12 T-PLL patients. 
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A. 
 
B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. A. Biocarta canonical pathways using TAS and differential gene expression. B. Predicted 
activation of cell cycle regulation pathway from IPA software overlaid with microarray expression 
data. Cell cycle checkpoint control at the G1 to S transition prevents the cell cycle from progressing 
when DNA is damaged. In response to DNA damage, ATM phosphorylates the tumor suppressor p53 
that interacts with p21 to block the activity of CDK2, preventing passage from G1 to S phase and 
harmful replication of damaged DNA. When the tumor suppressor RB is phosphorylated by cell cycle-
dependent kinases like CDK2 and CDK4, RB no longer interacts with E2F, and the cell cycle proceeds 
through the G1-S checkpoint. APR-246= Prima-1, BMS-387032=SNS-032. 
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19.5. SNS-032 inhibits TCR activation 
Across all cases, the CDK2/7/9 inhibitor SNS-032 was the most effective substance.  
To further elucidate the effect of SNS-032 on the most central growth-regulating 
receptor in T-cells, namely the TCR, Jurkat T-cells containing an NFAT-coupled 
luciferase reporter to read out the activation of this distal TCR signaling effector were 
treated with SNS-032 in the presence of TCR crosslinking anti-CD3 and anti-CD28 
antibodies. There was an NFAT-inhibition down to 45% in the presence of 1µM SNS-
032 (Fig 24A). According to our gene expression data, the TCR signaling pathway in 
T-PLL cells at baseline appears to be activated by the overexpression of PI3K, 
MEKK1, Ras, and NFAT in addition to the downregulation of inhibitory signals by 
CTLA4 (Fig 24B). 
A. 
 
  
 
 
 
 
 
B. 	   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. A. Jurkat NFAT luciferase reporter cells were incubated with the indicated concentrations 
of SNS-032 on a 384-well plate for 5 hours in the presence of purified anti-CD3 and anti-CD28 
antibodies. B. TCR signaling pathway from IPA software overlaid with gene expression data from RNA 
sequencing of 4 PLL patient samples and 2 CD4+ healthy control samples.  
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Discussion 
 
The aim of studies I–III was to characterize STAT-mutation negative LGL leukemia 
molecularly through the use of next-generation sequencing and gene expression 
analysis. Our previous findings revealed somatic mutations in the SH2-domain of 
either the STAT3 or STAT5B genes in approximately 40–50% of LGL leukemia 
cases2,19. However, as the STAT-mutation negative patients also harbor large 
expansions of LGL cells, other somatic mutations may drive the development of the 
disease.  
 
In study I, we showed that mutations in genes connected to the STAT-pathway and T-
cell activation/proliferation represent rare genetic triggers for T-LGL leukemia. 
Previous studies have shown that almost all T-LGLL patients exhibit the activation of 
STAT3, proving that this pathway is essential for the pathogenesis of LGL 
leukemia34,2,35. In this study, we also found that STAT3 was phosphorylated in 
patients without actual STAT3 mutations, indicating that other underlying factors are 
leading to the activation of the pathway. To further confirm this finding, T-LGLL 
patients were also clustered independently of their mutational status in the expression 
analysis. Therefore, the novel V995M mutation in the PTPRT gene is particularly 
interesting, as it may directly impact STAT3 activation and is the first evidence of 
other mutations affecting the JAK/STAT pathway in LGL leukemia.  
 
PTPRT is known to reverse the phosphorylation of Tyr705 on STAT3, a modification 
that is associated with STAT3 deactivation70. The PTPRT V995M mutation may 
thereby affect STAT3 activity by reducing the dephosphorylation of Tyr705, leading 
to an increased expression of STAT3 target genes. The mutation was found within the 
phosphatase domain D1 that is responsible for the proteins’ phosphatase activity. 
PTPRT is also frequently disabled in other cancers, such as lung and gastric cancer, 
where the hypermethylation of the promoter of PTPRT increases STAT3 activation 
and causes sensitivity to STAT3 inhibition165,166. The effect of other missense 
mutations in the D1 domain of PTPRT have been studied167 and the mutant proteins 
show a decrease in thermal stability and activation energy for phosphatase activity 
with respect to the WT protein. Inactivating mutations of the PTPRT gene may 
thereby have the same functional consequence as activating mutations of STAT3 in T-
LGLL patients.  
 
To clonally expand, T-cells must have an acquired survival advantage. In addition to 
defects in apoptotic pathways, survival pathways such as PI3K-AKT may also be 
activated in LGL leukemia patients34. Therefore, it was interesting to observe novel 
missense mutations in BCL11B and NRP1 in T-LGLL patients. BCL11B functions as 
a transcription factor required for normal T-cell development. The inactivation of 
BCL11B in mice leads to thymocyte developmental arrest and aberrant self-renewal 
activity168,169. Increased levels of BCL11B expression have been found to be 
associated with T-ALL170, and the inhibition of BCL11B expression in malignant T-
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cells results in apoptosis171. Mutations in BCL11B have also been reported in 9–16% 
of T-ALL patients22,172,173. 
 
NRP1, a receptor involved in axon guidance, is also expressed in human DCs and 
resting T-cells158. Interestingly, earlier studies have shown that NRP1 can play a role 
in the primary immune response during the formation of the immunological synapse 
between DCs and resting T-cells. The preincubation of DCs and resting T-cells with 
blocking NRP1 antibodies inhibited the DC-induced proliferation of T-cells. Thus the 
mutation in the NRP1 gene may affect the proliferation capacity of T-cells. 
 
These novel mutations affecting either the STAT3 or T-cell activation pathway were 
not found to be recurrent in our screening cohort (n=113). It seems that the STAT-
mutation negative patients are a more heterogeneous patient cohort, and therefore no 
similar dominant mutation as in STAT3 will be found in this group. However, in the 
Sanger sequencing screening assays, the primers covered only the mutation spots and 
nearby base pairs, and it is possible that by screening the whole genes, some 
additional mutations in the same genes will be found. Additionally, low frequency 
variants might go undetected due to the poor sensitivity of Sanger sequencing. To 
date, our group has performed the exome sequencing of 20 LGLL patients, and few 
recurrent mutations have been discovered. As mutations occurring in different genes 
with similar functions can drive a similar phenotype, further bioinformatical 
investigation of the different somatic variants should be performed to highlight 
pathways activated by mutations other than STAT3/5B in LGL leukemia.  
 
In studies II and III, additional STAT-mutations were revealed in the process of the 
exome sequencing of T-LGLL patients. First, a subgroup of CD8+ T-LGLL patients 
(4%) harboring mutations in the DNA-binding and coiled-coil domain of STAT3 were 
discovered. STAT3 activation is traditionally thought to be mediated through the 
dimerization interface containing the SH2-domain174. While the constitutive 
activation of STAT3 in LGL leukemia patients with SH2 hotspot mutations could be 
explained by an increased stabilization of STAT3 homodimers through enhanced 
hydrophobic attraction, the mode of activation through other domains is not as 
straightforward. Arginine residues within the DNA binding domain of STAT3 have, 
however, been found to promote phosphorylation and the intracellular shuttling of 
STAT3175. An arginine–glutamine exchange at the STAT3 moieties R414 and R417 
reduces the cytokine-dependent tyrosine phosphorylation of STAT3. The H410R 
variant seen in two LGL leukemia patients results in one extra arginine residue in this 
area, and it is plausible that this increase in hydrophilicity within the DNA binding 
domain mediates the activation of STAT3. The H410R mutation was also seen to be 
recurrent—one of the hallmarks of activating mutations.  
 
Previously, germline mutations in the DNA binding domain of STAT3 have been 
found in different immune disorders. In hyper IgE syndrome 176, dominant-negative 
mutations in the DNA binding domain leads to the diminished DNA binding ability of 
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the STAT3 dimer. There has also been some interest in using specific STAT3 
inhibitors in the treatment of other hematological malignancies, and recently a small 
molecule compound specifically targeting the STAT3 DNA-binding domain was 
found to inhibit cancer cell proliferation, migration, and invasion177. 
 
One CD8+ T-LGLL patient was found to harbor an F174S mutation in the coiled-coil 
domain of STAT3. This domain consists of four antiparallel helices and has previously 
been shown to be essential in receptor binding mediated by the SH2-domain as well 
as subsequent activation. The α1 region, containing the F174S mutation, seems to be 
crucial for STAT3 tyrosine phosphorylation stimulated by the epidermal growth 
factor (EGF) and IL6 as the deletion of the α1 abolished tyrosine phosphorylation of 
STAT3 in EGF-induced COS-1 cells178. One possible mechanism for the involvement 
of the coiled-coil domain in STAT3 phosphorylation is through the reinforcement of 
the protein-protein interaction between STAT3 and the activated IL6 receptor. 
Mutations in the coiled-coil domain have previously been seen in patients with 
inflammatory hepatocellular adenomas, where the E166Q mutant was shown to be 
constitutively phosphorylated on Tyr705, hypersensitive to IL6, and able to 
translocate to the nucleus 179. Persistent STAT3 activation has also been found in 
activated B-cell-like diffuse large B-cell tumors, where the M206K STAT3 mutation 
leads to increased cell proliferation180.  
 
In study III, exome sequencing identified novel somatic missense mutations in the 
transactivation domain of STAT5B in two CD4+ T-LGLL patients. Altogether, the 
STAT5B mutation frequency in the CD4+ T-LGL leukemia patients in our cohort was 
55% (6/11 patients). This is significantly higher than in the previous study of 211 
CD8+ T- and NK-cell LGL-leukemia cases, where STAT5B SH2 domain mutations 
were initially discovered in 2% of the cases19. The reported STAT5B-mutated patients 
had a much more aggressive disease course than that of typical T-LGLL. This finding, 
together with the high prevalence of STAT5B mutations in aggressive T-cell 
neoplasms, such as T lymphoblastic leukemia103,104, T-PLL4, and hepatosplenic T-cell 
lymphoma95, may suggest that STAT5B mutations predict a more aggressive clinical 
behavior than does the mutational activation of STAT3. However, in our cohort of 
STAT5B-mutated CD4+ T-LGLL patients, the disease course was quite indolent, and 
none of the patients with STAT5B mutations needed treatment during the observation 
time. The analysis of STAT5 target genes with ChIPseq has shown that STAT5B 
binds to molecules such as DOCK8, SNX9, FOXP3, and IL2RA, making it a key 
factor in T-cell development181. Together, these results suggest that STAT5B plays a 
central role in the development of T-cell neoplasms and that STAT5B mutations can 
be considered a novel diagnostic marker for CD4+ T-LGLL.    
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The diagnosis of T-LGL leukemia is often difficult, as symptoms and immuno-
phenotypical findings can resemble other reactive conditions, making the 
discrimination between malignant lymphoproliferation and reactive processes 
challenging. While T-cell clonality is considered an important finding supporting 
diagnosis, its significance remains controversial, as a proportion of healthy elderly 
individuals also present with non-neoplastic clonal T-cell expansions182. Therefore, 
consistent detection of STAT3 and STAT5B mutations in T-LGL leukemia represents a 
more definitive new diagnostic biomarker. Subsequently, the importance of screening 
the entire STAT3 and STAT5B genes in the diagnostic workup of T-LGLL is further 
emphasized.  
 
There also seems to be a clear division between the occurrence of STAT3 mutations in 
T-LGLL CD8+ cases versus the occurrence of STAT5B mutations in CD4+ cases. 
What could be the biological reason for this division? For STAT3, it is known that the 
genes of the activated IL6-STAT3 axis are overexpressed in CD8+CD57+ LGL cells 
due to chronic immune activation in T-LGLL37. Because the transcription of a gene 
has been found to correlate with the rate of mutagenesis183, this could explain the 
increased number of somatic STAT3 mutations. As for STAT5B, the upstream 
regulator IL-15 has been found to stimulate the proliferation and survival of CD4+ 
memory T-cells184. In a network model for T-LGLL survival signaling, IL-15 and 
PDGF were able to sustain a leukemic population185, and the overexpression of IL-15 
has been observed in T-LGLL, in autoimmune disorders, and during viral infections. 
Cytomegalovirus-derived stimulation has been associated with CD4+ T-LGL cases163, 
which may explain the higher STAT5B variant rate seen in CD4+ cases.  
 
Another leukemic disease where CD4+ cells are frequently STAT5B-mutated is T-
PLL. Although the mutation sites are overlapping, the resulting disease phenotypes 
are completely different, suggesting that in the more aggressive T-PLL, other 
aberrations such as chromosomal translocations are also driving the disease. In study 
IV, we systematically explored the diversity of drug responses in a large collection of 
T-PLL patient samples ex vivo using a drug screening platform and explored the 
associations of drug sensitivities with genetic aberrations. Such a strategy has proven 
successful before in BCR-ABL-driven leukemias, where axitinib was found to be 
effective in patients harboring the resistance-causing T315I mutation in ABL1135.  
 
The deep amplicon sequencing of JAK/STAT pathway genes in our patient cohort 
revealed recurrent mutations in 69% of cases. Single-gene mutations affected JAK3 
(29%), STAT5B (7%), JAK1 (6%), and IL2RG (1%), while coexisting multiple 
mutations were found in 26% of the cases, either within more than one gene or within 
the same gene. Compared to the previous genetic profiling of JAK/STAT pathway 
genes in T-PLL patients4,51,52,186, these results were highly concordant. For example, 
Kiel et al. (2014) reported a 76% JAK/STAT mutation frequency in T-PLL (38/50). 
Overall, the recurrent involvement of JAK/STAT signaling elements in non-
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synonymous mutations and indications of an activated JAK/STAT axis implicate a 
new actionable lesion to be explored in T-PLL. However, our sensitivity screen 
revealed that the ex vivo sensitivity of patient samples to JAK-inhibitors, such as 
ruxolitinib, momelotinib, tofacitinib and gandotinib, was not directly driven by these 
mutations in the JAK/STAT pathway. However, it was interesting to note that, for 
ruxolitinib, a JAK1/2 inhibitor, patients with the highly activating N642H STAT5B 
mutation were not as sensitive to the drug as patients with other STAT5B mutations. 
This could be due to the stability of the N642H mutant homodimer compared to the 
wild-type STAT5B (25-fold higher binding affinity), whereby the over-activation 
cannot be suppressed completely with JAK-inhibitors alone187.  
 
Generally, the clustering of drug sensitivity values in T-PLL revealed three patient 
subgroups driven by their resistance/sensitivity to HDAC-, HSP90-, and 
PI3K/mTOR/Akt-inhibitors. Surprisingly, despite the prevalence of the signature 
event of the activation of TCL1A (an established AKT coactivator) in the majority of 
T-PLL cases, only a subset responded to PI3K/AKT/mTOR inhibitors, such as AZD-
8055, MK-2206, apitolisib, and dactolisib. This might be due to the rather initiating 
role of TCL1A or its predominant effect in the context of TCR activation. On the 
other hand, the HDAC-inhibitors vorinostat, panobinostat, CUDC-101, quisinostat, 
and belinostat showed efficacy in the majority of PLL samples ex vivo. Recently, it 
was shown that treating relapsed or refractory PLL-patients with a combination 
therapy consisting of cladribine and an HDAC inhibitor re-sensitizes patients to 
alemtuzumab and results in better overall survival188. Further highlighting the 
importance of epigenetic regulation in PLL, mutations in genes encoding epigenetic 
regulators EZH2, TET2, and BCOR have been found in a number of T-PLL 
patients189.  
 
There was an outstandingly uniform sensitivity of virtually all cases to the CDK2/7/9-
inhibitor SNS-032, which had been tested in phase I for advanced chronic 
lymphocytic leukemia (CLL) and multiple myeloma (MM)190,191. These data are 
intriguing, since they indicate cell cycle dysregulation as a thus-far underappreciated 
central feature of T-PLL cells and implicate a novel vulnerability. As a potentially 
underlying genomic lesion, a deletion at 12p13 is found in approximately half of T-
PLL patients and has been associated with haplo-insufficiency of the CDKN1B gene 
encoding the cyclin-dependent kinase inhibitory protein p27190. In our expression 
analysis, we also found that CDKN1A, a protein that usually inhibits the activity of 
CDK2 and CDK4 complexes, was almost 3-fold downregulated in T-PLL patients. 
Also, CDK4, CDK18, and CDK20 were upregulated 2-fold. It was therefore not 
surprising that the combined analysis of the microarray expression data with ex vivo 
drug response data from 12 patients revealed the cell cycle regulating the RB pathway 
to be upregulated and addicted in some of the patients. Furthermore, SNS-032 also 
inhibited the activity of NFAT, a central transcription factor and effector molecule of 
TCR signaling and T-cell activation. It has previously been demonstrated that T-PLL 
cells usually express functional TCRs and that TCL1A enhances TCR signaling 
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mediating to a hyper-responsive and proliferative phenotype in the context of TCR 
engagement192.  
 
Another group of compounds with a striking effect in T-PLL samples ex vivo were the 
p53 re-activator Prima-1 Met and MDM2 inhibitors serdemetan and nutlin-3. While 
p53 mutations are frequently seen in many other cancers, in T-PLL these are not 
commonly found193. However, the overexpression and accumulation of wild type p53 
is common in T-PLL, which could also be seen in our expression data. The efficacy of 
the p53 activators ex vivo in our T-PLL cohort indicates a new actionable pathway 
where these compounds act as an on-switch for the accumulated p53 and induce T-
PLL tumor cell specific apoptosis. 
 
In T-PLL, pathways such as JAK/STAT, PI3K/Akt/mTOR, and cell cycle signaling 
can all be dysregulated by different mutations and translocations. Therefore, it is not 
enough to simply abolish the effect of one of these pathways to hinder the progression 
of the disease. Combining different compounds allows for synergy or sensitivity that 
could not be achieved by the single compound alone. In the clinical setting, unless the 
compound acts on multiple pathways itself, it is essential to find the perfect 
combination rather than relying on a single compound.  
 
Overall, the CDK-inhibitor SNS-032 and p53 activators stood out as drug classes with 
high efficacy across nearly all T-PLL samples and should be further tested in this 
disease. The acknowledgement of the fact that successful ex vivo results are not a 
guarantee for a therapy with the desired effect in the patient is important. However, 
compounds that do not function well on ex vivo cells are unlikely to perform well in 
vivo. As each round of ineffective treatment narrows the window of opportunity to 
help the patient, it can be just as vital to avoid unnecessary therapy regimens. The 
concept of individualized system medicine could improve patient outcomes and 
reduce health care costs by eliminating these rounds of expensive therapy that have 
little effect on cancer but can severely diminish quality of life. 
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Conclusions and future perspectives 
 
This thesis provides additional molecular information about the pathogenesis of T-
LGL leukemia. The discovery of additional STAT3 mutations outside the mutation 
hotspot in the SH2-domain of STAT3 further highlights the importance of screening 
the entire gene for STAT3 mutations in LGL leukemia patients, as it is a viable 
diagnostic marker. In the rarer CD4+ cases, the high frequency of STAT5B mutations 
presents with a novel diagnostic criteria alongside other established clinical and 
hematological parameters. Additionally, in STAT-mutation negative patients, the 
STAT-activation seems to be mediated through heterogenous genetic events only 
visible through exome or whole genome sequencing. As sequencing costs decline 
even further, applying exome sequencing to every patient becomes plausible, which 
would further increase our knowledge about the genetic landscapes of many diseases. 
In T-LGLL, further studies are warranted to establish additional genetic events or 
pathways that lead to T-LGL leukemia pathogenesis. A future task will be to develop 
new molecules or therapeutic strategies targeting the frequently activated JAK/STAT 
pathway. 
 
In T-PLL, ex vivo drug testing of primary patient cells has the potential to provide 
novel personalized drug candidates such as SNS-032 and Prima-1 Met. These 
observations hint at a centrally disturbed cell cycle regulation as well as a central role 
of TCR signaling in T-PLL. Despite high incidences of activating JAK/STAT 
mutations and indications on pathway activations, inhibitors of the JAK/STAT 
pathway gave variable responses. Overall, ex vivo drug response patterns in T-PLL 
did not closely correlate with known genetic aberrations, suggesting that screening for 
recurrent genetic biomarkers cannot easily be turned into effective therapeutic 
strategies in this problematic disease. This further emphasizes the importance of 
performing ex vivo drug screenings in combination with genomic analyses, as 
genomic data alone rarely lead to the right cancer drug for a patient. With drug 
screening, the phenotypic effect is already known, making the genetic analysis more 
focused on determining through which pathways a given drug is acting. As our 
understanding increases, we can look forward to more streamlined and effective drug 
discovery pipelines that use this information as a foundation. 
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